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Abstract 
Escherichia coli O157:H7 is responsible for over 70,000 cases of human illness every 
year in the United States.  Most cases occur in children under the age of five, the elderly, or other 
immune-compromised people.  A small percentage of these cases will develop a life threatening 
complication, hemolytic uremic syndrome.  Cattle are the reservoir host for E. coli O157:H7 and 
serve as the main source of contamination of meat products and other food sources.  The beef 
cattle industry is diverse with producers caring for as few as one to as many as thousands of 
cattle.  The first objective of this research was to examine three major production systems 
(conventional, organic, and natural) in the U.S. and the published performance effects of the 
various technologies used in each system.  The second objective was to determine if a newly 
licensed E. coli O157:H7 SRP
®
 (SRP) vaccine administered to cows pre-partum could achieve 
successful passive transfer in their offspring.  The third objective was to determine if colostrum 
obtained from SRP vaccinated heifers could protect against an oral challenge with an E. coli 
K99
+
 strain.  The fourth objective was to examine the shedding characteristics, health, and 
performance effects of calves born to SRP-vaccinated cows that also receive SRP vaccination 
themselves.  The technologies used in conventional beef cattle production resulted in significant 
improvements in health and performance of beef cattle.  Vaccinating cows pre-partum with SRP 
resulted in passive transfer in calves consuming their colostrum.  Calves that achieved successful 
passive transfer shed less E. coli K99
+
 and had improved fecal consistency compared to placebo.   
When calves were vaccinated with SRP at branding, weaning, and arrival to the feedyard there 
was no difference in fecal E. coli O157:H7 shedding on arrival to the feedyard or at harvest.  
Vaccinating calves with SRP had no effects on performance or health outcomes.  Vaccinating 
cattle with SRP may provide protection against other pathogenic E. coli strains and warrants 
further investigation.  The timing of vaccination appears to be an important consideration in 
order to ensure maximum vaccine efficacy. 
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Preface 
Chapters two and three in this dissertation entitled: “Analysis of modern technologies commonly 
used in beef cattle production: Conventional beef production versus nonconventional production 
using meta-analysis”, and “Characterization of specific passive immunity stimulated by 
vaccination of beef cows grazing native range with E. coli O157:H7-SRP
®” were submitted for 
publication in the Journal of Animal Science and The Bovine Practitioner, respectively. The text 
and figures within these chapters are formatted according to the guidelines that were specified by 
the journal. 
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CHAPTER 1 - Literature Review 
Escherichia coli   
Since their discovery in 1885 by Theodor Escherich, a German pediatrician, Esherichia 
coli have become one of the most studied group of bacteria.  In addition to study of the organism 
itself, Escherichia coli have been used as models to learn about biochemical reactions and 
processes that eventually gave rise to modern bacterial taxonomy; the organism is now being 
used as a carrier for gene libraries and phage research regarding disease treatment (Gyles 1994a).   
Escherichia coli belong to the family Enterobacteriacae and are morphologically, biochemically 
and genetically (DNA) related to the genus Shigella bacterium.  It has been proposed that the two 
genera be combined.  A reclassification has been delayed due to the adoption of the separate 
terminologies by medical microbiologists and the resulting confusion that would possibly ensue 
(Brenner 1984).  Escherichia is the first genus of the family Enterobacteriacae and can be 
identified morphologically as gram-negative rods that may be motile (due to a peritrichuris 
flagella) or non-motile (Brenner 1984).  All Escherichia are classified as facultatively anaerobic 
due to a dual respiratory and fermentive type of metabolism (Brenner 1984).  The colony 
morphology of E. coli can vary from rough to smooth with mucoid and slime-producing types 
possible.  Most strains of E. coli also ferment lactose which is used in culturing techniques from 
biological samples but not all strains of E. coli will ferment lactose.    Modern microbiological 
classification techniques rely on the amount of Guanine and Cytosine present in the organism to 
classify bacteria into genetic trees.  For E. coli, the mol% G + C of E. coli DNA is 48-52 (Orskov 
1984). 
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Classification 
With the emergence of a growing number of E. coli strains involved in disease outbreaks, 
early researchers began to classify subtypes of E. coli in order to describe differences observed in 
the course of particular outbreaks.  Kauffman (1947) was the first to classify E. coli based on 
serological methods (Lior 1994).  Thus was born the process and field of E. coli. serotyping that 
became the standard form of identification in medical microbiology.   
Identification of E. coli serotypes is based on serological reactions to somatic antigens O, 
K, H, and F.  The „O‟ antigens are derived from the outer lipopolysaccharide (LPS) membrane of 
E. coli and are not inactivated by heat (Lior 1994).  There are two groups of „O‟ antigens: the 
first group is classified as immobile during electrophoresis and tends to be associated with extra-
intestinal disease; the second group is classified as mobile during electrophoresis and tends to be 
associated with dysentery-like disease (Orskov & Orskov 1972).  There are also a number of 
reports of cross-reactions of „O‟ antigens between Shigella, Salmonella (Orskov and Orskov 
1984; Stenutz et al. 2006), Vibrio cholera, and Citrobacter strains (Winkle et al. 1972).   
The „K‟ antigen designation was proposed by Kauffmann (1947) to describe the inability 
of bacterial suspensions to agglutinate until being heated to 100°C.  This group has largely been 
abandoned for the purpose of research due to an inability to produce antibodies in rabbits and 
lack of clinical usefulness.  The remaining „K‟ antigen designations are K1 & K5 in human 
diseases (Lior 1994) and K88 & K99 in animal diseases (Jones & Rutter 1972; Jin & Zhao 2000; 
Smith & Linggood 1972).   
The „H‟ antigens are associated with the protein flagellin in the flagella of motile E. coli 
(Lior 1994).  Most of the E. coli „H‟ antigens are specific and show little to no cross-reactivity 
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(Ewing 1986).  The „H‟ and „O‟ antigens are regarded as key markers of the pathogenicity of the 
various strains of E. coli of both intestinal and extraintestinal diseases (Lior 1994).    
The „F‟ antigens represent proteins associated with fimbrae or pilli that are present on the 
outer surface of E. coli.  Fimbrae and pilli are necessary for attachment and colonization of E. 
coli to mucosal surfaces (Beachey 1981).  One strain of E. coli can display several fimbrae of 
differing antigenic types.  The number of „F‟ antigens continues to increase despite the difficulty 
of serotyping it.  Two of the fimbrial types are associated with K88 (F4) and K99 (F5; Lior 
1994).   
Pathogenic Classification 
Another form of classification for E. coli strains is related to enteric diseases and was first 
proposed by Neter et al. (1955).  This classification system combines multiple serogroups with 
similar pathogenic effects under a single entity called enteropathogenic (EPEC) E. coli.  The 
system has been expanded relatively recently to include six major groups of enteric disease-
related E. coli that are based on virulence mechanisms of group members (Kaper et al. 2004; 
Nataro & Kaper 1998):  1) enteropathogenic E. coli (EPEC), 2) enterohemmorhagic E. coli 
(EHEC), 3) enterotoxigenic E. coli (ETEC), 4) enteroaggregative E. coli (EAEC), 5) 
enteroinvasive E. coli (EIEC), and 6) diffusely adherent E. coli (DAEC).   
Enteropathogenic E. coli (EPEC) are one of the most studied and understood group of 
pathogenic E. coli (Kaper et al. 2004).  Most E. coli microbiologists agree on the classification 
criteria for EPEC as production of a characteristic attaching and effacing lesion on histology on 
small intestinal cells and no production of Shiga, Shiga-like, or verocytotoxins (Kaper 1996).  
Even though EPEC do not produce toxins they still cause disease in humans and animals (Spears 
et al. 2006).   
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The majority of the virulence mechanisms for EPEC and EHEC are encoded on „O‟ 
islands or plasmids.  The recent sequencing of an EPEC strain E2348/69 (Iguchi et al. 2009) and 
comparisons made to E. coli O157:H7 strains (Hayashi et al. 2001 & Perna et al. 2001) revealed 
that 69 of the 177 „O-specific‟ islands have >90% homology across EPEC and EHEC strains 
(Spears et al. 2006); however, 14 of these islands have less than 55% homology between the two 
groups indicating the potential for frank differences in virulence mechanisms (Spears et al. 
2006).   
The ability to produce the characteristic attaching and effacing lesion of EPEC is encoded 
by genes on the pathogenicity island called the locus of enterocyte effacement (LEE; McDaniel et 
al. 1995).  The LEE encodes an outer-membrane protein, intimin, which is involved in the 
intimate attachment of E. coli to the enterocyte and also encodes for the type III secretion 
system, chaperones, and effector proteins responsible for the characteristic pedestal formation 
between the bacteria and the enterocyte (Kaper et al. 2004).   
A subdivision of EPEC bacteria has also been described based on the presence or absence 
of the EAF (i.e., EPEC adherence factor) plasmid that encodes a type IV pilus called the bundle-
forming pilus (BFP). BFP are important for initial binding to host cells, mediating interbacterial 
adherence, and formation of three-dimensional micro-colonies (Giron et al. 1991 & Cleary et al. 
2004).  The first EPEC subdivision, termed typical EPEC, contain the EAF plasmid.  
Conversely, atypical EPEC lack the EAF plasmid.  In industrialized countries, the predominant 
EPEC isolated from human diarrheal cases are atypical; however typical EPEC are the 
predominate isolates in developing countries (Trabulsi et al. 2002; Chen & Frankel 2005). 
Enterohemorrhagic E. coli (EHEC) is one of the most intensely studied groups of E. coli.  
Its founding strain is E. coli O157:H7.  It was identified in 1982 during the investigation of 
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bloody diarrhea outbreaks in humans in Oregon, Michigan, and Canada (Riley et al. 1983 & 
Stewart et al. 1983).  Escherichia coli O157:H7 is also the predominant EHEC responsible for 
hemorrhagic colitis and hemolytic uremic syndrome (HUS) in the U.S.; other non-O157 EHEC 
group members are more common in other parts of the world (Naylor et al. 2005).   
The defining characteristic of the more than 100 E. coli strains in the EHEC group is 
production of verotoxin or shiga-like-toxin (Lior 1994).  These toxins are encoded on what are 
believed to be acquired bacteriophages.  There are two main variants of these toxins. Shigella-
like toxin 1 (Stx1) is nearly identical to the enterotoxin of Shigella dysentariae (O‟Brien & 
Holmes 1987; Nakao & Takeda 2000) and Shigella-like toxin 2 (Stx2) is the toxin most often 
associated with human disease (Boerlin et al. 1999).  The difference between Stx1 and Stx2 in 
the development of human disease may be due to differences in the B-subunit of the toxin 
(Fraser et al. 2004).  The B-subunits determine the cell-binding specificity and allow the 
translocation of the A-subunit into the cell.  Once inside the cell the A-subunit is cleaved to 
produce a peptide with N-glycosidase activity that inhibits protein synthesis by cleaving of the 
28s ribosomal RNA (Spears et al. 2006).  Lingwood (1996) and Lingwood et al. (1987) 
demonstrated that the B-subunit binds to the receptor Gb3/CD77 to initiate translocation of the 
A-subunit.  CD77/Gb3 receptors are present on human endothelial cells and also on kidney 
glomerular cells but not bovine endothelial cells (Boyd & Lingwood 1989; Adler & Bollu 1998).  
This difference in initial binding is likely one of the reasons we see hemorrhagic disease in 
humans and not in the carrier animal, cattle.  This class of E. coli will be discussed in greater 
detail in the section specifically on E. coli O157:H7 that follows. 
Enterotoxigenic E. coli (ETEC) first emerged in 1971 in human males in India with acute 
diarrhea (Gorbach et al. 1971; DuPont et al. 1971); however, the relationship between isolating 
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E. coli that produced enterotoxin and colibacillosis was first identified in calves by Smith and 
Halls (1967).  The distinguishing characteristic of this group of E. coli is the production of 
enterotoxin and the presence of colonization factor antigens (CFA).  At least 21 distinct CFA 
have been identified in human derived ETEC, which are distinct from CFA in animal derived 
ETEC.  ETEC target the small intestine and colonize along the mucosa where they produce one 
or both of two enterotoxins, heat-labile toxin (LT) and heat-stabile toxin (ST; Elsinghorst 2002).   
The initial adherence of the ETEC to the mucosa is facilitated by the CFA binding to the 
host cell using one or possibly multiple binding sites located along the filamentous structure 
(Gaastra and Svennerholm 1996).  The colonization factor for binding sites on host enterocytes is 
host specific.  An example is the host specificity observed in E. coli strains expressing K88 
fimbriae; they only cause disease in pigs (Jin and Zhao 2000; Francis et al. 1999).  After CFA 
binding, the organism colonizes on the surface of the mucosa to allow for a localized secretion of 
enterotoxin (Zafriri et al. 1987).  The host response to the toxin leads to a net excretion of fluid 
from the enterocyte into the small intestine, especially in the jejunum (Banwell et al.1971).  This 
net fluid loss results in the most common clinical sign of E. coli infection, watery diarrhea.  
Forty-six percent of ETEC isolates release ST alone, 25% release LT alone and approximately 
29% of isolates express both ST and LT (Wolf 1997).   
LT toxins are structurally and functionally similar to the cholera toxin produced by 
Vibrio cholera (Spangler 1992).  Two types of LT have been characterized.  LT-I toxins are 
present in both human and animal isolates and can be neutralized by cholera toxin antisera.  LT-
II toxins are primarily found in animal derived isolates but cannot be neutralized by cholera toxin 
antisera.  Interestingly, the production of LT-II has not been associated with diarrhea 
(Elsinghorst 2002).   
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Similar to LT toxins, there are two types of heat-stable (ST) enterotoxins.  In addition to 
being heat-stable, these toxins are secreted locally into the gastrointestinal medium where they 
can have a broader effect range (Rasheed et al. 1990; Okamato & Takahara 1990; Kupersztoch et 
al. 1990).  The first type, ST-I toxin is functionally distinct from ST-II.  ST-I bind to the 
extracellular domain of guanylate cyclase C (GC-C) that is found in the brush-border membrane 
of intestinal epithelial cells (Hasegawa et al. 1999).  The ST-I toxin increases extracellular 
secretion of chloride by binding the GC-C receptor more effectively than guanylin (Caprick & 
Gariepy 1993).  This binding increases intracellular cGMP which stimulates chloride excretion 
by crypt cells and inhibits sodium and chloride adsorption by villus epithelial cells. The net 
increase is to increase fluid accumulation in the gut lumen via osmotic pull (Forte et al. 1992).  
ST-I toxin is homologous to EAST1 toxin in enteroaggregative E. coli (Savarino et al. 1991), as 
well as other heat-stable toxins found in Yersinia enterocolitica and Vibrio cholera non-O1 
strains (Elsinghorst 2002).  ST-II toxin has been implicated in inciting histologic damage to the 
intestinal epithelium and also increasing intestinal motility; however, ST-II is restricted mainly 
to porcine ETEC strains and only recently has been found to be active in rats and mice if 
protected from proteolysis via trypsin in the gut (Whipp et al. 1987; Hitotsubashi et al. 1992). 
ST-II is rarely the only enterotoxin expressed by porcine ETEC strains.  The sole role of ST-II 
toxin in the pathogenic diarrhea process is likely minor.  The reason for its prominence in disease 
causing ETEC strains is more likely due to its genetic code location being on plasmids that also 
encode LT, ST-I, colonization factors, drug resistance, colicin production and transfer functions 
(Gyles 1994b).  
Enteroaggregative E. coli (EAEC) is the pathotype described most recently (Nataro et al. 
1987; Vial et al. 1988) of the six major E. coli pathotypes.  It is characterized by its “stacked 
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bricks” appearance on HEp-2 cells (Nataro et al. 1987) and lack of secretion of heat-labile or 
heat-stable enterotoxins (Nataro & Steiner 2002).  EAEC has been linked to diarrheal outbreaks 
in travelers and in HIV patients in both developed and developing nations (Nataro et al. 2006; 
Ruttler et al. 2002).  EAEC is most associated with inducing a persistent, mucoid diarrhea in 
humans.  Interestingly, there is no known pathogenic animal strains (Fang et al. 1995; Nataro et 
al. 1995).  Data from a recent meta-analysis indicated that EAEC is a cause of acute diarrhea in 
15% of children in developing countries and in 4% of children in industrialized nations (Huang 
et al. 2006a).  The ability of EAEC to elicit clinical disease is complicated due to the interaction 
of EAEC virulence heterogeneity and differing host tolerance levels, which result in varying 
levels of clinical disease (Elias et al. 2002; Nataro et al. 1995; Huang 2006b).   
Clinical disease induction by EAEC involves three stages (Huang et al 2006b): stage 1 
involves adherence to the intestinal mucosa via aggregative adherence fimbriae (AAF) and 
adherence factors; stage 2 involves production of mucus by the bacteria and the host cell forming 
a biofilm over the surface of the enterocyte; stage 3 involves release of toxins eliciting an 
inflammatory response, mucosal toxicity, and intestinal secretion.   
Stage 1 is driven by the three structural subunits of the AAF which are encoded on the 
60-65 MDa pAA plasmid.  Two of these structural subunits of the AAF are regulated by a 
transcriptional regulator AggR (Huang 2006b) that also regulates the expression of a low-
molecular weight secretory protein termed dispersin (Sheikh et al. 2002). Dispersin is 
responsible for the dispersal of EAEC across the mucosa which allows for the adherence and 
aggregation process to begin.  This protein has also been found to be highly immunogenic which 
makes it a potential vaccine candidate (Nataro et al. 1995).  Stage 2 of the pathogenesis involves 
excessive mucus production from both the bacteria and the intestinal mucosa.  The formation of 
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this dense biofilm aids in the survival of EAEC and is the source of the characteristic mucoid 
diarrhea.  Little is known about biofilm production in EAEC but it does appear to be dependent 
on two genes (Fis & yafK) that are also mediated by AAF (Sheikh et al. 2001).  Stage 3 involves 
the release of toxins with the corresponding inflammatory response, mucosal toxicity and 
intestinal secretion.  The overall, combined action of these toxins is destructive to the tips and 
sides of intestinal villi and enterocytes (Huang et al. 2006b).   
The three most described toxins involved in the EAEC pathogenesis are plasmid-encoded 
toxin (Pet), EAEC heat-stable enterotoxin (EAST1) and Shigella enterotoxin 1 (ShET1; Huang et 
al. 2006b).  It should be noted that, EAST 1 is not unique to EAEC but can be found also in 
ETEC, EHEC, EPEC and in DAEC (Savarino et al. 1991).  The host immune response to 
infection with EAEC and subsequent clinical signs can vary depending upon the genetic 
composition of the individual (Jiang et al. 2003); however, none of the above genes or virulence 
factors is conserved among all EAEC.  Few of these factors are unique to EAEC.  This, 
combined with host-to-host susceptibility variation, results in sporadic and inconsistent estimates 
of prevalence and pathogenicity (Huang et al. 2006b; Weintraub 2007). 
The Enteroinvasive E. coli (EIEC) class of organisms shares a number of somatic 
antigens with shigellae and incites similar diarrheal disease (DuPont et al. 1971).  This intimate 
relationship between shigellea and EIEC has existed for centuries.  Infections affect millions 
with diarrhea/dysentery each year and may be responsible for 170,000 deaths annually (Niyogi 
2005; Black 1993).  The unique features of this group of E. coli are the presence of a large 
virulence plasmid, their ability to invade epithelial cells, and their ability to then move from cell 
to cell (Parsot 2005).  EIEC is relatively simple to distinguish it from normal-flora E. coli 
because EIEC is non-motile.  In addition, 70% of isolates cannot ferment lactose and do not 
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decarboxylate lysine.  Conversely, they share these features with Shigella species.  This, along 
with the similar disease presentation in humans, has translated into many researchers and 
epidemiologists combining EIEC and Shigella into a common disease category called 
Shigellosis.  Humans are the reservoir host for EIEC; very few animal hosts have been identified 
(Day & Maurelli 2002).   
Day and Maurelli (2002) described the four hallmarks of virulence for EIEC: 1) ability to 
induce diarrhea, 2) ability to invade epithelial cells of the intestine, 3) ability to multiply inside 
the epithelial cells, and 3) ability to spread from cell to cell.  EIEC organisms benefit from the 
initial diarrhea in the jejunum because it provides a transport mechanism to the colon.  In order 
to cause clinical disease, EIEC must then go on to invade the epithelium of the large intestine 
(LaBrec et al. 1964).  Entry to the epithelial cell is initiated by the type III secretory system 
analogous to that described for EPEC strains (Parsot 2005).   
The third hallmark of virulence is replication once inside the intestinal epithelium.  
Strains that have reduced ability to multiply once inside the epithelial cell are unable to elicit 
clinical disease (Formal et al. 1965).  Strains that result in clinical disease must arrive in the 
colon, invade the epithelial cell, and multiply within the epithelial cell, and then move from cell 
to cell while remaining in the confines of the intracellular space.  The fourth hallmark of 
virulence was demonstrated by using organisms that had the capacity to enter epithelial cells and 
multiply but lacked the ability move from cell to cell.  These organisms failed to induce clinical 
disease (Day and Maurelli 2002).  The ability of EIEC strains to invade epithelial cells and move 
from cell to cell is encoded on a large (220 kb) virulence plasmid (Parsot 2005).  A unique 
quality of EIEC is that it can regulate the expression of virulence in response to temperature.  
Strains grown at 37°C are able to invade epithelial cells; however, strains grown at 30°C are 
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unable to invade.  This control mechanism mimics similar mechanisms of other pathogens such 
as Salmonella Typhimurium, Yersinia species and Listeria monocytogenes (Small and Falkow 
1988; Parsot 2005). 
Diffusely adherent E. coli (DAEC) are genetically related to EAEC (Czeczulin et al 
1999).  DAEC are differentiated from EAEC by a characteristically diffuse pattern of binding to 
HEp-2 cells in culture (Nataro & Steiner 2002).  There have been no published outbreaks of 
enteric disease in humans or animals attributable to DAEC, nor have volunteer challenge studies 
yielded disease induction (Tacket et al. 1990).  In contrast, epidemiological studies have noted an 
association with diarrhea in both developing and industrialized nations in adults and children but 
not infants (Baqui et al. 1992; Gunzburg et al. 1993; Jallat et al. 1993; Levine et al. 1993).  The 
role of DAEC in urinary tract (UTI) and kidney infections in humans is much more established 
(Servin 2005).  Due to the inability to demonstrate or replicate enteric disease induction with 
DAEC very little about the pathogenesis is known.  Recently, more work has been completed on 
the pathogenesis and virulence factors with regard to the DAEC strains involved in human UTI 
and pyelonephritis.  Genetic and molecular studies proposed that DAEC be placed into two 
groups.  The first group of DAEC are those strains that posses Afa/Dr adhesions, and the second 
group are strains that posses the adhesion involved in diffuse adherence (AIDA-I; Servin 2005). 
Escherichia coli   O157:H7 
Escherichia coli O157:H7 is the flagship organism for the EHEC group and can cause a 
wide range of symptoms from no detectable illness to life threatening illness (Griffin & Tauxe 
1991).  Escherichia coli O157:H7 is the main organism responsible for causing the potentially 
fatal hemorrhagic colitis and hemolytic uremic syndrome in humans (Riley et al. 1983).  
Ruminants, especially cattle, are regarded as the primary reservoir of E. coli O157.  Infection 
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usually occurs through consumption of contaminated food products, contaminated water sources, 
direct contact with animals, or direct contact with infected persons (Rangel et al. 2005).  The 
infectious dose of E. coli O157 required to cause clinical disease is quite low at 50-100 
organisms (Tilden et al. 1996).  The incubation time from ingestion of the organism to the 
manifestation of clinical disease ranges from 1-9 days, with an average of 3-5 days (Griffin & 
Tauxe 1991).  In 2009, this organism had an incidence of 0.99 per 100,000 people in the United 
States with the highest incidence of morbidity occurring in children < 4 years of age (CDC 
2010).  Relatively low incidence enabled the U.S. to meet its Healthy People 2010 target of ≤ 1.0 
cases per 100,000 people of STEC O157 infection (U.S. Department of Health and Human 
Services 2000).  The greatest percentage of people hospitalized occurred in those aged > 50 years 
old; 1.5% of those resulted in death (CDC 2010).  Each year approximately 73,000 people 
become infected with E. coli O157 (Mead et al. 1999), costing the U.S. economy approximately 
$1 billion per year (USDA-ERS 2001) in health care and life-related costs.  Of the tracked and 
reported foodborne illnesses, E. coli O157 infections have a relatively low incidence compared 
to those of Salmonella (15.19 per 100,000), Campylobacter (13.02), Shigella (3.99) and 
Cryptosporidium (2.86; CDC 2010).  The interest in the organism is likely due to the small 
percentage of infections that result in the life-threatening complication known as Hemolytic 
Uremic Syndrome (HUS).  In 2008, there were 64 cases of HUS in people under the age of 18 
years; two-thirds of these cases occurred in children under the age of 5 years (CDC 2010).  There 
has been a disproportionate amount of research time and money dedicated towards the study of 
this single serotype and its virulence properties because of this debilitating and even fatal 
response to infection. 
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Research efforts over the last 30 years have identified two major virulence factors that 
contribute significantly to disease induction and an additional area of putative virulence factors 
that, when combined, contribute to the survivability of E. coli O157 in the host.  These virulence 
mechanisms have been the entire subject matter of several books dedicated to in-depth 
descriptions of each factor and their effects on the survival and pathogenicity elicitation of the 
host (Donnenberg 2002; Sussman 1997).  The two key features of E. coli O157 that significantly 
increase its virulence are shiga toxin production and presence and functionality of the 
chromosomal pathogenic island termed the Locus of Enterocyte Effacement (LEE).  The lesser-
known putative factors are usually controlled via the plasmid O157 (pO157) which is capable of 
replicating independently of chromosomal DNA (Lim et al. 2010).   
Shiga Toxin Production 
The production of shiga toxin (Stx) is the most important virulence factor of E. coli 
O157, as it is considered essential for disease induction in humans.  Stx is a bacteriophage-
encoded cytotoxin with two main types, Stx1 and Stx2.  Strains can posses the genetic material 
to encode for either Stx1, Stx2 or both. Strains encoding Stx2 are more toxic to humans than 
strains possessing Stx1 or both Stx1 and Stx2 (Boerlin 1999).   
One of the differences between Stx2 & Stx1 may lie in the B-subunit (Fraser 2004).  Both 
Stx1 & Stx2 are AB5 toxins, so called because the B-subunit is responsible for binding to the 
host-specific cell receptor called Gb3 (Nataro & Kaper 1998).  The Gb3/CD77 receptor is 
present in human endothelial cells and human kidney glomerular cells (Boyd & Lingwood 1989; 
Alder & Bollu 1998).  The amount and type of Gb3 receptor present on the cell surface 
determines the susceptibility of the cell to Stx (Gyles 2007).  After binding, the A subunit is 
internalized into the cytoplasm via receptor-mediated endocytosis (Sandvig et al. 2004).  It is 
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transported subsequently to the Golgi apparatus and endoplasmic reticulum where it inhibits 
protein synthesis occurring at the 28s rRNA of the 60s ribosome and induces apopotosis (Gyles 
2007; Lim et al. 2010).  The dissemination of Stx to other than the intestine, and its effects on 
them, is not well understood.   
Locus of Enterocyte Effacement  
Adherence to intestinal cells is associated with highly pathogenic strains of E. coli O157 
serotypes (Boerlin 1999).  Not all Shigella-like Toxin producing E. coli (STEC) produce the 
characteristic attaching and effacing (AE) lesion.  STEC that are eae-positive (i.e.,  E. coli 
attaching and effacing) tend to attach to epithelial cells more strongly and produce the 
characteristic AE lesion (Nataro and Kaper 1998).  These eae-positive strains are also 
responsible for the majority of infections that result in HUS and, thus, have been identified as a 
significant risk factor (Ethelberg et al. 2004).  A pathogenicity island on the eae gene termed the 
locus of enterocyte effacement (LEE) is of particular interest.  It encodes most of the proteins 
necessary for the formation of the AE lesion.    
The LEE is organized into 5 major operons, LEE1 to LEE5.  Operons LEE1 to LEE3 lead 
to the formation of the type III secretory system which is a unique mechanism for transfer of 
proteins between the bacterium and the enterocyte to which it attaches.  Operon LEE4 forms the 
protein translocation system used to transfer material between the cells.  Operon LEE5 is 
responsible for the outer membrane system.  Using intimin and its own receptor (i.e., 
translocated intimin receptor; TIR) the outer membrane system facilitates attachment to the 
enterocyte (Gyles 2007).    
The type III secretory system is not unique to E. coli.  It can be found in many other 
bacteria such as Yersinia, Shigella, Salmonella and Pseudomonas.  Half of the 25 proteins that 
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code for the secretory mechanism are conserved in most of the type III systems (Mota & 
Cornelis 2005).  The type III secretion system uses a syringe and injector-type of secretory 
system that links the cytoplasm of the bacterium to that of the enterocyte.  Once the two cells are 
penetrated, effector proteins are transferred to the enterocyte through the structure.  One of these 
proteins is TIR which binds to enterocyte proteins and is inserted into the membrane of the 
enterocyte.  There it acts as a receptor for intimin from the bacterial surface.  This signals a 
number of cascades that result in intimate attachment of the bacterium and enterocyte via re-
arrangement of the intestinal cell architecture.  These architectural changes result in loss of the 
microvilli, pedestal formation, and accumulation of the supporting cytoskeletal proteins beneath 
the bacteria that make the AE lesion visible under microscopy (Gyles 2007; Mota & Cornelis 
2005; Kenny 2002). 
Putative Virulence Factors 
Several products of the pO157 have been shown to contribute to the virulence of E. coli 
O157 infection.  The magnitude of their contribution is likely small, which has made it difficult 
to definitively associate them with virulence using traditional epidemiologic approaches.  Lim et 
al. (2010) proposed using the presence of the pO157 and comparing it to virulence as a proxy for 
the combined effect of its gene products.  These authors then assert that the presence of the 
pO157 is associated with increased virulence.  The pO157 contains genes responsible for the 
formation of several products: a hemolysin (ehxA), catalase-peroxidase activity (katP), a type II 
secretion system (etp), serine protease (espP), a metalloprotease (stcE), putative adhesion (toxB), 
and an Eae gene-positive conserve fragment (ecf; Lim et al. 2010).  All of these products have 
been shown to contribute to a specific aspect of E. coli function or survival, primarily in in-vitro 
models.  Individually, none have been associated with increased virulence in appropriate animal 
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models.  Recent work with a bovine model reported that absence of the pO157 in strains of E. 
coli O157:H7 decreased the survivability of the organism under acidic conditions and altered the 
propensity of it to colonize the rectal-anal junction (RAJ; Lim et al. 2007; Sheng et al. 2006). 
An important virulence factor necessary for E. coli O157 to survive the first body defense 
in the human stomach is resistance to a pH of 1.5-3.0.  If it is able to survive the strongly acidic  
environment of the stomach chances of colonizing the lower gut increase.  Organisms that 
successfully evade destruction in the stomach employ an acid-tolerance response (ATR) system.  
This system uses a glutamate decarboxylase and a gene encoded antiporter system to consume a 
proton and transport the product extracellularly, effectively maintaining a neutral pH in the 
cytoplasm (Thorpe et al. 2002).   
Other factors not as well defined or understood that could also contribute to virulence are 
heat resistance, salt resistance, presence of EAST1 enterotoxin, presence of an adherence-
conferring molecule (lha), and different regulators and effectors of the LEE (Lim et al. 2010).  
The recent whole genome sequencing of two strains of outbreak associated E. coli O157 (Perna 
et al. 2001; Hayashi et al. 2001) and of the pO157 (Burland et al. 1998) greatly increased the list 
of possible putative virulence factors. 
Epidemiology 
Cattle are the most important animal reservoir of E. coli O157:H7 in North America, 
whereas sheep are the most important animal reservoir in Australia (Gyles 2007).  Prevalence 
estimates for E. coli O157 shedding on cow-calf ranches have been quite variable and dependent 
on time of year and whether the calf population or the cow population was under study.  Gannon 
et al. (2002) found that 25% of calves were shedding E. coli O157 during the first 7 weeks of 
life; however, prevalence fell to 0% when calves were moved to pasture.   One week prior to 
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weaning, the shedding prevalence was 0-1.5%.  Two weeks post-weaning, the prevalence was 6-
14%.  A similar trend was seen in the cows where 7 weeks post-partum E. coli O157 prevalence 
was 2-18% and then upon moving to pasture the prevalence fell to 0%.  Riley et al. (2003) found 
that, in a Southeastern US herd, 3% of samples from reproductive-age females were positive for 
E. coli O157; 9.1% of the cows sampled had at least one positive fecal test over a three month 
sampling window.   
Sargeant et al. (2000) also showed low prevalence (1.3-1.9%) in cow-calf herds in 
Kansas.  This study also indicated that a calf whose dam was shedding E. coli O157 was not 
more likely to shed O157 than a calf from a dam never identified as shedding O157.  Conversely, 
an Australian dairy study estimated that a calf was 2.2 times more likely to shed VTEC if the 
dam was also shedding VTEC (Cobbold and Desmarchelier 2000).  Laegreid et al. (1999) 
reported only 6.9% of the cultures positive in a multi-herd, multi-state study; however, herd level 
prevalence was 87% with 63-100% seroprevalence to O157 antigen.  Shedding in a herd was 
positively correlated and high titers in serum. Furthermore, the force of infection was greatest in 
late summer and prior to weaning and declined during the first 6 weeks on feed.  In a Canadian 
study, farm-level E. coli O157 prevalence was 45% with an animal-level prevalence of 6%.  This 
study described significant risk factors associated with shedding and found that cattle 
supplemented with corn silage in the winter were 7.64 times more likely to shed O157 as cattle 
not supplemented with corn silage.  In summary, little cow-calf sector E. coli O157 
epidemiology research has been done.  This is most likely due to the temporally long data 
collection process, low prevalence, erratic prevalence, unknown impact of shedding at the cow-
calf stage on food safety, and greater interest directed at the feedlot and post-harvest sectors.  
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There have been a number of studies conducted examining the prevalence of E. coli 
O157 in feedlot cattle (reviewed in Rhoades et al. 2009).  Fecal prevalence has ranged from 
0.26% to 28% with considerable variation even within pen, depending on time of year and on 
sample processing procedures (Renter & Sargeant 2002).  A large study conducted by Hancock 
et al (1997) indicated low animal-level prevalence (1.3% - 4.6%), moderate pen-level prevalence 
(13.3% - 52.5%), and high feedlot-level prevalence (61%; 61/100 feedlots).  Although conducted 
in 13 states in the Midwestern U.S., no significant regional distribution of E. coli O157 shedding 
was identified.  In contrast, Lejune et al. (2004) found a pen-level prevalence of 100% and a 
fluctuating animal-level prevalence ranging from 15% on arrival to the feedlot to 28% two weeks 
after arrival. Animal-level prevalence then decreased to 5-10% for the remainder of the study.  
Sargeant et al (2003) examined E. coli O157 prevalence in 73 feedlots located in four states, 
which represented approximately 15% of the fed cattle in the U.S. at the time of the study. They 
reported an overall E. coli fecal prevalence of 10.2%, pen-level prevalence of 52%, and a 
feedlot-level prevalence of 95.9%.  Other studies reported animal-level prevalence to be 28% 
(Elder et al. 2000), 23% (Smith et al. 2001) and 15.7% (Chapman et al. 1997).   
The true epidemiologic picture of E. coli O157 from discovery to present day has been 
difficult to contextualize as newer, more sensitive techniques for detection have been developed.  
One of the key differences between older studies that reported relatively low prevalence and 
more recent studies that reported greater prevalence is that the modern studies used 
immunomagnetic separation after the enrichment process.  This step has reportedly increased the 
sensitivity of the combined culture technique by 100-fold (Chapman et al.1994).  This has made 
it difficult to tell if there is a true increase in the prevalence, or an increase in diagnostic test 
sensitivity or both (Renter & Sargaent 2002) since the first reports in the 1980‟s. 
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Other studies have been performed to estimate the prevalence of E. coli O157 in other 
cattle production settings.  Estimates from studies conducted outside of the U.S. on veal calves 
have estimated the prevalence of E. coli O157 to be low (0-9%) compared to adult cattle (16.1%-
61.2%; Bonardi et al. 1999; Cobbaut et al. 2009; Heuvelink et al. 1998).  In a recent longitudinal 
study conducted in Ontario on white veal calves, researchers estimated E. coli O157 calf-level 
prevalence to be 3.2%, while nearly 100% of the calves were positive for exposure to shiga 
toxin-producing organisms (Cristancho et al. 2008).  Cobbault et al (2009) also compared 
prevalence of E. coli O157 between dairy farms and mixed dairy and beef farms. They reported 
that dairy farms had greater prevalence than beef and veal farms (61.2%, 22.7% and 9.1% for 
dairy, beef, and veal, respectively) and that the prevalence on mixed farms was significantly 
greater than that on beef farms (44.4% and 22.7% for mixed and beef, respectively).  This is in 
contrast to Hancock et al. 1998 and Bonardi et al. 1999 who reported similar E. coli O157 
prevalence between dairy and feedlot cattle.   
Study of E. coli prevalence among different ages of adult cattle has produced mixed 
results.  Some studies report that young adult cattle had greater prevalence of E. coli O157 
compared to older adults (Van Donkersgooed et al. 1999; Hancock et al. 1997; Yilmaz et al. 
2002).  Conversely, Riley et al. (2003) found that older animals had greater E. coli O157 
prevalence than did younger adults in a Texas study (13.5% and 8.2% for older and younger 
cattle, respectively).  The effects of age on E. coli prevalence remain unclear. These factors are 
often confounded by production practices, geographic locations, breeds, and diet types (Rhoades 
et al. 2009).   
The range of E. coli O157 prevalence estimates from hide and oral cavity samples from 
cattle varies widely (7.3% to 61.9%; Keen & Elder 2002; Barkocy-Gallagher et al. 2003; Rivera-
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Betancourt et al. 2004; Elder et al. 2000; O‟Brien et al. 2005). Such a wide range precludes 
giving a single meaningful estimate of prevalence.  There have been mixed results as to which 
sample, fecal or hide, gives a more accurate estimate of true prevalence.  Barkocy-Gallagher et 
al. (2003) reported that hides had a greater prevalence of E. coli O157 than did fecal (60.6% and 
5.9% for hide and fecal, respectively), whereas other researchers have reported the opposite 
(Elder et al. 2000; Woerner et al. 2006).  Reid et al. (2002) illustrated that location of the sample 
on the hide may be an important factor in detecting E. coli presence.  They isolated E. coli O157 
from 22.2% of brisket samples but from only 4.4% of flank samples and 3.3% of rump samples.  
This affirms comments by Elder et al. (2000) in which that they asserted that the brisket was the 
location most likely to give a true reflection of animal-level E. coli prevalence because it 
represented contamination from the bedding material in pens, whereas E. coli presence on flanks 
and rumps might represent cross-contamination from pen mates during lairage.  Other studies 
examining only hide prevalence have reported relatively high (53% - 75.7%) E. coli O157 
prevalence (Arthur et al. 2007; Arthur et al. 2004; Rivera-Betancourt et al. 2004).  Hide 
contamination of the carcass is generally accepted as one of the most important factors leading to 
contaminated meat products (Edwards & Fung 2006). 
The production and processing of meat products is governed by Chapter III under Title 9 
in the Code of Federal Regulations (CFR).  Section 417 in chapter III describes the points on 
Hazard Analysis and Critical Control Points (HACCP; Hulebak & Schlosser 2002).  The 
implementation and refinement of HACCP at harvest plants has been largely responsible for the 
significant reduction (i.e., over 40%) in the incidence E. coli O157-related illnesses in the U.S. 
from 1996-2004 (CDC 2005).   Harvest plant estimates are based on the location within the 
fabrication process the samples are collected.  The four commonly reported stages for sample 
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collection are pre-evisceration, post-evisceration, post-intervention, and chilled (Rhoades et al. 
2009).  Woerner et al. (2006) studied 15 lots of cattle from 12 feedlots were cultured at the 
feedyard and then followed through the fabrication process at the harvest facility.  They reported 
fecal E. coli O157 prevalence of 24.7, 14.7, 27.6, 10.1, 1.4, and 0.3% for pen floor, hide, colon, 
pre-evisceration, post-evisceration, and final intervention samples, respectively.  In that study, 
animals from pens with a pre-harvest fecal prevalence greater than 20% were associated with 
increased prevalence estimates in samples from the harvest facility; however, there was no 
difference in animals from low (<20%) prevalence pens.  There appears to be a moderate 
correlation (r = 0.67) between positive fecal samples at the feedlot and positive hide samples at 
harvest.  Elder et al. (2000) studied 341 carcasses and reported fecal, hide, pre-evisceration, post-
evisceration, and final intervention E. coli O157 prevalence of 28, 11, 43, 18, and 2%, 
respectively.  These authors also noted that there may be a relationship between fecal prevalence 
and carcass contamination. They suggested strategies enlisted on the farm may aid in the 
reduction of the risk of E. coli O157 infection from contaminated food.   
Other studies have also reported low E. coli O157 prevalence on carcasses prior to 
evisceration, on carcass samples post-final intervention, on chilled carcasses, or in meat 
(Chapman et al. 2001; Barkocy-Gallagher et al. 2003; Arthur et al. 2004; Rivera-Betancourt et al. 
2004). 
Pre-harvest Control 
In a simulation study, Jordan et al. (1999) estimated that the greatest reduction in carcass 
contamination may result from vaccination with an agent that decreases the amount of E. coli 
O157 shed in the feces.  This seems reasonable because of the strong relationship between fecal 
prevalence and carcass contamination (Elder et al. 2000; Loneragan & Brashears 2005).  As a 
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result, a number of research groups have been focused on development and analysis of pre-
harvest, farm-level interventions to decrease E. coli O157 fecal shedding in cattle. These 
interventions are designed to protect the meat supply and to decrease environmental 
contamination of soil and water that may be consumed directly or indirectly by humans. 
The most intuitive method for the control of bacterial infections or bacterial colonization 
is the use of antimicrobials administered either directly to the animal or delivered to the animal 
in the feed.  Ransom et al. (2003) reported a reduction of over 40% in cattle treated with 
neomycin alone, neomycin in combination with a probiotic, or a probiotic combined with a 
vaccine.  It should be noted that the use of neomycin to control the fecal shedding of E. coli 
O157 in cattle is not approved by the FDA at the time of this writing.  Also of significant 
concern is the perpetuation of antibiotic resistance to non-target species and their role in human-
acquired infection.  There is increasing pressure on animal agriculture to eliminate non-
therapeutic uses of antibiotics; therefore, research investigating antibiotic administration to 
control E. coli shedding has been limited.   
The effects of feed-grade ionophores on E. coli O157 shedding have been studied in vitro 
and in vivo with no demonstrable effect (Edrington et al. 2003; Edrington et al. 2006).  Two 
studies performed on cattle fed forage and corn diets were interpreted to suggest that there may 
be an interaction between diet and antimicrobial treatment (Van Baale et al. 2004; McAllister et 
al. 2006).  These studies reported that there was a reduction in E. coli O157 shedding by cattle 
fed a forage-based diets but not by cattle fed a concentrate-based diet. Another closely-related 
approach is the use of bacterially-derived proteins such as colicins or bacteriocins that create a 
porous membrane in bacteria leading to death of the organism (Schamberger & Diez-Gonzalez 
2002). 
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Other approaches to pre-harvest intervention involve feed probiotics or prebiotics.  
Probiotics are live microbial preparations that are added to the diets of cattle to improve the 
intestinal microbial balance in a manner that benefits the animal (Fuller 1989).  Prebiotics are 
sugars and other organic compounds that are not processed or used by the host but are used by 
the resident intestinal microflora (Steer et al. 2000).  The probiotic combination of Lactobacillus 
acidophilus and Propionibacterium fruedenreichii has reduced E. coli O157 fecal shedding from 
27% to 16% and hide prevalence from 14% to 4% under field conditions. There also appears to 
be an improvement in growth efficiency that may offset product cost, making this probiotic a 
possible component in a complete E. coli O157 reduction program (Elam et al. 2003; Younts-
Dahl et al. 2004; Stephens et al. 2007).  To date, no cost-effective strategies using prebiotic feed 
additives in food animals have been reported(Oliver et al. 2009).  Using a similar approach 
known as competitive exclusion, Zhao et al (1998) demonstrated a reduction in E. coli O157 by 
feeding a mixture of non-O157 E. coli. 
The effects of diet on E. coli shedding has been extensively studied (reviewed in 
Callaway et al 2009).  Cattle on barley-based diets had greater fecal prevalence and increased 
quantity of E. coli O157 than cattle on corn-based diets (Berg et al. 2004).  Cattle fed a steam-
flaked corn diet had increased E. coli O157 prevalence compared to cattle on a dry-rolled corn 
diet (Fox et al. 2007).  This has led to the theory that grain types or grain-processing methods 
that increase fermentable carbohydrate reaching the distal intestine will increase the amount of 
colonic VFA available and will increase the E. coli O157 population. Tkalcic et al. (2000) 
compared fecal prevalence of E. coli O157 among forage-fed cattle and grain-fed cattle after 
inoculation with O157. They reported that grain-fed cattle consistently had a greater fecal 
prevalence than that of forage-fed cattle.  Similarly, a series of projects examining the effects of 
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distiller‟s grains (wet and dry) on E. coli O157 fecal prevalence found that cattle fed diet 
containing distiller‟s grains usually had increased fecal prevalence of O157 (Jacob et al. 2008a; 
Jacob et al 2008b).  It is important to note that the difference in fecal prevalence was only at the 
individual-animal level whereas there was no difference in the pen-level fecal prevalence and 
only at a single time point (d 122), with no difference at the final sampling time point at the 
animal or pen-levels.  It is difficult to say with certainty how feeding distiller‟s grains may affect 
fecal E. coli O157 shedding.  Forage feeding reduced fecal E. coli O157 shedding in cattle but 
reduced live bodyweight (Callaway et al. 2009). 
Another intuitive method for control of bacterial infection and colonization is through the 
development and use of an effective vaccine.  Two different vaccines have been developed and 
tested in production settings in cattle.  The first vaccine is based on the type III secretory proteins 
(TTSP) that are key components in attachment to the intestinal epithelial cell.  Potter et al. (2004) 
demonstrated a 58.7% lower risk of recovering E. coli O157 in the feces of vaccinates over 
controls.  Moxley et al. (2009) then followed with a dose determination study and reported a 
65% reduction in the risk of recovering E. coli O157 from feces of cattle vaccinated three times 
verses controls.  The second vaccine that has been developed is based on Siderophore Receptors 
and Porin proteins (SRP) that are involved with bacterial iron acquisition (Chakrabroty et al. 
2007; Stevens & Thomson 2005).  This vaccine manufactured by Epitopix (Willmar, MN) 
received conditional licensure in 2009 in the U.S.  Thornton et al. (2009) in an experimental 
inoculation study demonstrated a reduction in the number of vaccinated cattle shedding E. coli 
O157 in the feces and a tendency towards a reduction in the concentration of O157 when they 
were shedding.  Similarly, Thomson et al. (2009) in a field study found that vaccinated cattle had 
an 85.2% reduction in risk of shedding E. coli O157 in the feces and a 98.2% reduction in the 
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concentration of fecal E. coli.  Wileman et al. (2010) also examined the response of calves born 
to cows that received the vaccine prior to calving and found that passive transfer of E. coli 
O157:H7 specific antibody does occur under field conditions in beef cattle.  An effective vaccine 
developed for on-farm control of E. coli O157 could have additional benefits extending to other 
food sources from decreased environmental contamination (Jordan et al. 1999; Elder et al. 2000). 
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CHAPTER 2 - Analysis of modern technologies commonly used in 
beef cattle production:  Conventional beef production verses non-
conventional production using meta-analysis 
Abstract:  Conventional feeding systems use pharmaceutical products not allowed in 
natural or organic systems for finishing cattle.  This review of data compares the performance 
effects (ADG, G:F, DMI) of technologies used in conventional feeding programs that are 
prohibited in organic and/or natural programs. The technologies evaluated were steroid implants, 
monensin, tylosin, endectocides, and metaphylaxis with any antimicrobial.  For inclusion in this 
analysis, studies were conducted in North America; reported randomization to treatment group; 
utilized beef cattle; contained an untreated control group; and were sourced from peer reviewed 
journals.  Forest plots were used to visually examine the data for trends towards a uniform effect 
of the technology on the outcomes of interest (ADG, DMI, G:F).  Technologies that displayed a 
uniform response compared to negative controls on the forest plot were then analyzed using 
mixed models.  Examination of forest plots for endectocides, steroid implants, monensin and 
metaphylaxis technologies appeared to show performance advantages for treated cattle relative to 
cattle in negative control groups.  An insufficient number of studies met the inclusion criteria to 
conduct meta-analyses comparing endectocides, monensin or tylosin to negative controls.  
Average daily gain in feeder cattle given metaphylaxis on arrival was 0.11 kg/d (P < 0.01) 
greater relative to cattle that did not receive metaphylaxis on arrival.  Implanting heifers 
increased ADG by 0.08 kg/d compared to non-implanted controls (P = 0.09).  Implants had no 
effect on G:F (P = 0.14) in heifers or on DMI (P = 0.44) relative to non-implanted control 
heifers.  Implanting steers was associated with greater ADG by 0.25 kg/d (P < 0.01) and DMI by 
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0.53 kg/d (P < 0.01) relative to non-implanted control steers.  Implants also improved G:F in 
steers relative to non-implanted steers by 0.02 (0.17 vs. 0.15; implanted vs. controls, P < 0.01) (n 
= 21 studies).  When average estimated differences in ADG and G:F for implanted and non-
implanted steers were incorporated into a breakeven model, implanted steers had a $77 per head 
lower cost of production than non-implanted steers and $349 per head lower cost of production 
than organically raised steers.  These data illustrate the importance of capturing premiums when 
operating natural and organic production systems to maintain economic viability.  
 Keywords: Beef cattle, conventional, finishing performance, meta-analysis, non-
conventional 
 
INTRODUCTION 
There is an increasing focus on organic and natural beef production in the United States.  
Conventional feeding systems use pharmaceutical products not allowed in organic systems for 
finishing cattle and do not utilize certified organic feedstuffs as defined under the national 
organic program (NOP, 2008).  The recent USDA regulations for natural beef production 
prohibit the use of growth promoting hormones and animals that have received antimicrobials.  
However, the new rule does allow the use of ionophores for the control of coccidiosis 
(USDA/AMS 2009).  Until recently there has been no standard definition of “natural beef 
production” which has lead to inconsistencies between “natural” beef production systems.  There 
is very limited research comparing an entire beef cattle production system with pharmaceutical 
technologies versus one that excludes those technologies (Fernandez and Woodward, 1999; 
Sawyer, 2003; Berthiaume, 2006), thus limiting the ability to accurately predict the performance 
differences between cattle in the different systems.  Contrary to a review article, a meta-analysis 
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provides a method of examining existing literature critically and in a quantitative manor, 
accounting for within and between trial variance, in order to provide an overall estimate of effect 
of a given question(s) based on existing data.  The aim of this study was to evaluate the 
performance effects (ADG, DMI, and G:F) and health effects (morbidity and mortality) of 
pharmaceutical technologies used in feedlot cattle that may be routinely excluded from non-
conventional production systems. This report uses the techniques of forest plot analysis and 
meta-analysis to evaluate the technologies of steroid implants, monensin, tylosin, endectocides, 
and metaphylaxis with any antimicrobial on arrival and their effects on the performance and 
health of feedlot cattle.  In addition, liver abscess risks of cattle receiving tylosin verses cattle not 
receiving tylosin were also examined.     
MATERIALS AND METHODS 
Data Gathering  
The question was: What is the difference in ADG, G:F, DMI, morbidity, mortality and liver 
abscess risks in feedlot cattle with and without pharmaceutical technologies in North America?   
Manuscripts were identified through PubMed, and Commonwealth Agricultural Bureau (CAB) 
electronic databases from February 2008 thru April 2008.  A variety of search terms were used to 
identify articles that possibly contained relevant information about the review questions (Table 
1).  Each search contained at least one search term from each category.  After retrieving the 
citations, each title and abstract was read by the first author and retained for further evaluation if 
it mentioned at least one of the treatments and at least one of the outcomes of interest in beef 
cattle.  Further, the Intervet Schering Plough Animal Health (Kenilworth, NJ) and Texas Tech 
University North American TBA Implant Database (TTU Implant Database, 1999) was used to 
identify studies utilizing steroid implants.  The information contained in the database is 
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searchable. The manuscripts and technical bulletins from which the data were sourced are linked 
from the site.  All articles were cross-referenced with abstracts obtained through the PubMed and 
CAB database searches, and technical bulletins from implant database were included as well.  
These manuscripts and technical bulletins were assessed using the same inclusion criteria except 
for being from peer reviewed sources.  Only data from studies using a single implant treatment 
(i.e. no re-implant) with a contemporary non-implanted control group were considered relevant.  
The implant data was further sub grouped into implant studies utilizing heifers and studies 
utilizing steers to attempt to mitigate the amount of variability in the data sets. 
After identifying relevant studies based on the title and abstract, the complete manuscript was 
obtained and critically evaluated.  Studies were only retained for further consideration if the 
study was conducted in North America, used randomization to allocation of treatment group; 
used beef breed animals and contained an untreated control group.  Manuscripts that did not meet 
all of the above criteria were excluded from further consideration.  Data were then extracted 
from the remaining studies.  Data was extracted by recording the point estimates for ADG, DMI, 
G:F, mortality, morbidity, presence of liver abscess and corresponding SE for each treatment 
group, description of experimental unit, number of experimental units, and sex of cattle for each 
of the manuscripts.  
 For studies that reported results for different dose levels (i.e. monensin 100, 200, 300 mg/hd) 
the average treatment effect was calculated via a calculated mean of the treatment responses 
from the data at the individual dose levels. This data extraction approach was required for five 
studies in which authors were not able to separate out the information and report it separately.  
The measure for SE of the treatment effects in these studies was a pooled SE as reported in the 
manuscript.  When studies reported a pooled SE, this was converted to a standard deviation by 
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multiplying the pooled SE of the difference in sample means by the square root of the number of 
experimental units.  The number of experimental units depended on what was defined as the 
experimental unit, the animal or the pen i.e. for  2-arm parallel comparison with 100 animals in 
10 pens per arm and treatment allocated at the pen level , then n = 20.  The standard deviation 
was then squared to obtain the variance, which was used in the meta-analysis.   
 
Data Analysis 
Forest plots using the R-statistical package and the rmeta and meta packages (R 
Development Core Team, Vienna, Austria) were used to visually assess if the effect of the 
technology on the outcomes of interest (ADG, DMI, G:F) was uniform across studies. For this 
graphic approach, the production outcome and standard deviations were used to calculate the 
difference between groups and these data used for the forest plot.   In a forest plot each study is 
listed on the left hand side of the graph individually.  The horizontal line listed next to each study 
represents a 95% confidence interval for the difference between groups for continuous outcomes.  
The size of the shaded box in the middle of the horizontal line represents the relative weight of a 
study compared to the other studies.  The weight is a reflection of the number of experimental 
units involved in the study, i.e. the greater the number of replicates the greater the weight.  All of 
the studies are then oriented in relation to the large vertical line listed as the “zero” line or no 
effect line.  This line represents a situation in which the difference between the two treatments 
equals zero.  Studies to the right of the null value indicate a positive value and studies to the left 
have a negative value.   Technologies were considered to be uniform by the first author when 
50% of the point estimates (boxes) on the forest plot were to one side of the null effect line.   
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For the continuous outcomes ADG, DMI and G:F, technologies considered to display a 
uniform response compared to negative controls were analyzed using general linear mixed 
models in Proc Mixed of SAS (SAS Inst. Inc., Cary, NC).  In brief, each model of continuous 
outcome variables (ADG, DMI, G:F) contained one fixed effect (steroid implants, monensin, 
tylosin, endectocides, metaphylaxis), a random intercept effect for each study, and a repeated 
effect to incorporate a within-study variance for each study (van Houwelingen 2002, St. Pierre 
(2001).  To define the covariance parameter for the between-study variance (range: 0.01 to 1.0 
by 0.01), values for the within-study variance for each study (extracted from the literature) were 
used to create the profile likelihood function and resultant 95% confidence interval for the 
between-study variance (van Houwelingen 2002).  The only change from the form described by 
van Houwelingen (2002) was the addition of the least squares means command to generate 
model-adjusted means and SE for fixed effects and establish a single overall treatment effect for 
each technology that showed a statistically significant difference (alpha < 0.10).  The model-
adjusted means and SE for ADG, DMI and G:F, when statistically significant, were used to 
derive a 95% confidence interval for the summary effect and incorporated into a standardized 
feedlot breakeven model. 
The metaphylaxis morbidity and mortality data and the tylosin liver abscess incidence data 
were analyzed with generalized linear mixed models with a logit link and binomial distribution 
using the Glimmix procedure of SAS (SAS Inst. Inc., Cary, NC).  The outcome variables were 
modeled in an events/trial format where the denominator represented the total number of cattle 
within a group and the numerator included only those with the outcome of interest (morbidity, 
mortality, liver abscess).  A repeated statement was used to account for the multiple observations 
within studies, and a random intercept term was used to account for the potential correlations 
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among groups within studies.    Metaphylaxis was included in the model statement as a fixed 
effect, and when significant, model adjusted estimates were transformed from the logit form to 
generate the estimated probability of treatment or death if receiving metaphylaxis, or having liver 
abscesses if consuming tylosin, respectively.  Therefore, the estimated probability represents a 
cumulative incidence or risk of these adverse health events occurring at some point during each 
trial. 
 
Breakeven Model 
A standardized feedlot breakeven model commonly used by feedlot consultants and 
managers to assess the economics of feeding a pen of cattle with user defined inputs was used 
(Thomson, 2008).  The economic model assumptions are listed in Table 2.  Based on an average 
of the ADG and G:F reported in Berthiamune (2006), Fernandez and Woodward (1999), and 
Sawyer (2003), we used an ADG of 1.30 kg/d and a G:F of 0.14 to predict the breakevens for 
“natural” raised calves.  The model was then used to simulate implanting the “natural” calf and 
the estimated differences in ADG and G:F from the meta-analysis were used to estimate a 
breakeven.  And finally, the model was used to predict feeding the “natural” calf an organic diet.  
For the organic breakeven, the days on feed was increased by 20 d (Fernandez and Woodward, 
1999) and the organic feed costs were multiplied by 1.5 (USDA, 2003) to simulate the feedlot 
performance and feed cost differences of organic cattle.  A sensitivity analysis was performed for 
organic feed prices ranging from 1.25 to 1.75 of conventional feed prices. 
RESULTS 
A total of 14,311 citations were identified by the initial electronic search.  After examining 
the titles and abstracts for possible relevance and removing duplicate citations, 140 manuscripts 
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were retrieved for quality assessment and data extraction.  After quality assessment and 
application of inclusion criteria, 91 treatment to control comparisons were identified from 51 
manuscripts (Table 3). The three most frequent reasons studies were excluded were failure to 
include an untreated control group, failure to report variation of the outcome either as a standard 
deviation or SE, and failure to use randomization to allocate animals to treatment groups.  
Based on visual assessment the forest plots, use of endectocides (Figure not shown), 
steroid implants (Figures 1 and 2), monensin (figure not shown) and metaphylaxis (Figure 3) 
showed a performance advantage for treated cattle relative to the cattle in negative control 
groups, i.e. more than 50% of point estimates to the right of the null.  Tylosin studies did not 
show a consistent advantage in treated cattle relative to control cattle with respect to ADG, G:F 
and DMI.  An insufficient number of studies met the inclusion criteria to conduct a meta-analysis 
comparing endectocides, monensin or tylosin.  Therefore, a summary effect measure was only 
calculated for metaphylaxis and implant data sets. 
Meta-analysis and Breakeven  
Average daily gain in feeder cattle receiving metaphylaxis using a variety of antibiotics on 
arrival was 0.11 kg/d (95% CI = 0.10 to 0.13, P < 0.01) relative to cattle that did not receive 
metaphylaxis on arrival (Table 4).  The use of implants in heifers was associated with increased 
ADG by 0.08 kg/d compared to non-implanted controls (95% CI = 0.01 to 0.15, P= 0.09).  The 
use of implants in heifers was not associated with differences in G:F (P = 0.14) or DMI (P = 
0.44).  The use of implants in steers was associated with 0.25 kg/d greater ADG (95% CI = 0.23 
to 0.27, P < 0.01) and 0.53 kg/d greater DMI (95% CI = 0.45 to 0.61, P < 0.01) relative to non-
implanted control steers.  The use of implants was also associated with increased G:F in steers 
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relative to non-implanted steers by 0.02 (0.17 vs. 0.15; implanted vs. controls, 95% CI = 0.018 to 
0.022, P  < 0.01).  
The point estimates of differences in ADG and G:F for implanted and non-implanted steers 
were incorporated into the breakeven model.  The model suggests that implanted steers were 
associated with $77 per head lower cost of production than non-implanted steers fed similar 
diets.  Also, implanted steers fed a non-organic diet had a $349 per head lower cost of production 
than non-implanted cattle fed an organic diet assuming being sold on the same market.  The 
sensitivity analysis performed on the assumption of organic feed price being 1.5 of conventional 
feed prices.  These results indicated that the cost of production for organic beef, as well as 
conventional, is highly sensitive to feed price.  For each 10% increase in the price of organic 
feed, the breakeven estimate increased approximately $54/head.  The simulations did not 
incorporate morbidity and mortality effects. 
Morbidity, Mortality and Liver Abscesses 
For cattle that received metaphylaxis using a variety of antibiotics upon arrival to the 
feedyard, morbidity was estimated at 29% (95% CI = 21.2% to 38.58%) compared to 55% (95% 
CI = 44.46% to 65.14%) in the cattle that did not receive metaphylaxis (P < 0.01; Figure 4).  For 
cattle receiving metaphylaxis on arrival to the feedyard, mortality was estimated to be 1.8% 
(95% CI = 1.05% to 3.12%) compared to 3.8% (95% CI = 2.30% to 6.50%) for cattle not 
receiving metaphylaxis (P < 0.01; Figure 4).  Cattle not fed a ration containing tylosin had an 
estimated 30% (95% CI = 18.62% to 44.77%) risk of having liver abscesses compared to 8% 
(95% CI = 4.43% to 14.07%) in cattle consuming tylosin (P < 0.01; Figure 4).   
DISCUSSION 
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This study suggests performance effects for several modern technologies on North American 
beef cattle production.  Studies that compared a single implant to no implant in steers indicated 
an improvement in ADG by approximately 0.25 kg/day and improved G:F by 0.02.  Over a 210-
d feeding period this could result in a 52.5 kg live weight difference between implanted and non-
implanted steers.  This is approximately a 17% improvement in ADG and a 9% improvement in 
G:F which is in agreement with other reports of expected implant performance when compared 
to non-implanted cattle (Bartle, 1992, Preston 1999, Duckett and Andrae 2001).   
Science based performance and economic expectations can be achieved by using the meta-
analysis performance results in a breakeven model.  These data can provide an accurate 
indication of the premiums necessary to offset increased costs of producing beef in alternative 
systems compared to producing beef in conventional beef production systems.  The use of 
metaphylaxis on arrival resulted in an estimated 53% reduction in subsequent morbidity 
treatments and an estimated 27% reduction in mortality losses compared to cattle not receiving 
metaphylaxis. 
Feeding tylosin to feedlot cattle reduced the liver abscess risks from 30% to 8% in the studies 
examined.  This study did not look at the severity of liver abscesses and relate it back to 
subsequent performance.  This might explain why there was no significant difference in ADG 
between tylosin treatment groups.  Nagaraja and Lechtenburg (2007) in their review of liver 
abscesses reported significant variation in the performance effects of abscessed livers and stated 
that it was likely a function of severity.  The small or mild liver abscesses likely have less of a 
negative impact on performance than do larger or more severe abscesses.  
In general, the use of these technologies has increased the amount of beef produced per 
animal and has produced that beef more efficiently and economically (Lawrence and Ibarburu, 
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2006).  The benefits of using these modern technologies are not just limited to the three 
performance indicators that we measured.  There are additional impacts, such as control of bloat, 
coccidiosis, and external parasites, which occur with use of technologies but were not included in 
this analysis due to a dearth of published data.  There are still other technologies that were not 
addressed in this study that are commonly used to control the reproductive cycling in heifers or 
increase the amount of HCW in the final period of feeding.  As technologies are integrated into 
conventional feeding systems, their effects on economical and biological efficiencies in beef 
cattle production, as well as their effect on environmental and animal welfare issues will need to 
be examined.   
This meta-analysis was broader in scope than some of the previously published meta-
analyses in beef cattle production (Van Donkersgoed, 1992; Wellman and O‟Conner, 2007).  
Most meta-analyses try to answer the question, “Is one treatment more favorable than another in 
terms of a single or small number of outcomes?”.  McPhee et al. (2006) demonstrated the use of 
meta-analysis for applications examining multiple treatments with multiple outcome effects.  The 
current study was designed to examine the effects of one production practice, which has multiple 
treatments and multiple potential effects, as compared to another production practice that 
excludes all of the treatments.  This by default introduced a large amount of heterogeneity into 
the meta-analysis which would preclude reporting any summary of effect statistics used in 
traditional meta-analyses.  There was no test for homogeneity done on the data sets.  The 
existence of heterogeneity was assumed, and was the basis for the use of the random effects 
model as was described previously.  Van Houwelingen (2002) stated that, “heterogeneity might 
be present and should be part of the analysis even if the test for heterogeneity is not significant.”  
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St. Pierre (2001) also remarked that the use of the random effects mixed model provides a more 
accurate estimate of values by allowing for the random effect of different studies. 
One major source of bias is the approach used to identify studies.  Published studies and 
technical reports are strongly subject to publication bias.  There is a potential likelihood that 
studies which failed to show an effect have decreased opportunity to be published. Therefore, the 
source of papers may represent a biased subset of papers and if this is the case, may provide a 
best case scenario difference.  Unfortunately, it is not possible to estimate the magnitude of 
publication bias that may or may not exist.  Further, it is feasible that for “truly effective 
treatments” publication bias may not occur for different reasons – i.e. if a treatment is truly 
effective the need to continue to publish the same outcome many times is diminished.  The 
consumer of the review must make their own decision about the potential for publication bias 
and its impact.  
Summary effects were reported in this study for two main reasons.  First, the heterogeneity in 
the meta-analysis was limited as much as possible for such a broad question through the critical 
manuscript review and inclusion criteria, and the remaining heterogeneity reflects the reference 
population for which the models seek to represent.  There is a significant amount of variation 
between different segments of the beef cattle industry in terms of cattle management and 
production system goals.  One producer may use a single implant, while others may use up to 
four in a calf‟s lifetime.  Secondly, this study will hopefully stimulate more quantitative research 
on the health and performance effects of natural and organic beef production.   
None of our summary statistics disagreed with smaller related reports in the literature.  In 
addition, our summaries seem to agree with anecdotal responses seen in the field.  Based on a 
study of just 54 cattle, Fernandez and Woodward (1999) reported that a 39% greater selling price 
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would be required to compensate for the performance reductions incurred with organic beef 
production as compared to conventionally produced steers.  Our simulated breakevens indicate 
that a $0.62/kg live BW premium is required for an “organically-raised” animal to generate the 
equivalent net return compared to a “conventionally-raised” animal.  Fernandez and Woodward 
(1999) also reported a 0.03 decrease in G:F and a 16% (0.26 kg/day) decrease in ADG in 
“organically-raised” steers compared with “conventionally-fed” steers.  Our study also found that 
the difference in feed cost makes up the majority of the difference in costs between the two 
systems.  In a 40-head study, Berthiaume et al (2006) found that non-implanted cattle had a 16% 
reduction in HCW, a 31% reduction in quality grade and would require a 15% greater premium 
over implanted cattle to remain equivalent.  Our simulated breakeven model suggests that a 
“naturally” raised steer will have to generate at least a $0.14/kg live BW weight premium to 
generate an equivalent return as a conventionally raised steer.  Sawyer et al. (2003) also 
demonstrated similar results in 64-steer study.   Lawrence and Ibarburu (2006; 2008) also used 
meta-analysis to examine the effects of removal of all pharmaceutical technologies from all 
segments of beef production.  There were no statements as to article selection or the process for 
examining the evidentiary value of the articles.  Nonetheless, they estimated that the affect of 
removal of pharmaceutical technologies from the feedlot phase of production to be $155/hd 
which is similar to the estimate calculated from this study.  Our model only examined the effects 
of a single implant and used only the difference due to that single implant in the analysis.  
Lawrence and Ibarbaru attributed $71 of the $155/hd difference to implants whereas this analysis 
estimated $77/ hd benefit.  There are likely benefits in ADG and G:F for multiple implant 
programs that could explain the remainder of the difference between our estimates and those of 
Lawrence and Ibarbaru.  
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The primary purpose of a meta-analysis is to critically evaluate existing literature and 
provide an overall summary of effect.  This report was able to provide an overall summary of 
effect for a limited number of the technologies.  The secondary purpose of a meta-analysis is to 
highlight reasons why studies were not found and/or included in the analysis.  For this report the 
secondary purpose may be as important as the primary purpose.  We found that there has been a 
shift away from including untreated controls in many studies in an effort to compare one 
technology to another.  As the natural and organic industries continue to grow, it will be 
important to evaluate the effect of various technologies on beef production efficiency.  It is also 
important that the beef industry conducts further field trials comparing natural or organic 
systems directly to conventional systems.  It is equally important to report the data more 
thoroughly by reporting measures of variation between treatment groups and between measured 
outcomes, and accurately describing methods used for blinding as we had to exclude several 
studies for these reasons.  It is possible the analysis presented here overestimates the direct 
impact of these technologies due to publication bias.  However, it is also likely that these 
products are highly effective as they are widely adapted in conventional production systems.   
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 Figure 1: Forest plot of implanted steers and corresponding ADG: overall mean effect and 
95% confidence interval listed by the single implant used in the study.  All are referenced 
from Texas Tech implant database. 
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Figure 2: Forest plot of implanted steers and corresponding DMI: overall mean effect and 95% 
confidence interval listed by the single implant used in the study.  All are referenced from Texas 
Tech implant database. 
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Figure 3: Forest plot of metaphylaxis use and corresponding ADG: overall mean effect 
and 95% confidence interval listed by manuscript and study. 
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Figure 4:  Risks of treatment and death of cattle receiving and not receiving 
metaphylaxis and risks for liver abscesses in cattle receiving and not receiving tylosin 
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Table 1:  Search terms used in PubMed and CAB databases.  A word from each category 
was selected and combined with the word “and” to form search phrases to identify any relevant 
manuscripts. 
Population Treatment Outcomes 
Beef Metaphylaxis ADG 
Cattle Prophylaxis Average Daily Gain 
Cow Mass Medication FE 
Bovine Antibiotic Feed Efficiency 
Steer Ionophore DMI 
Heifer Monensin Dry Matter Intake 
Calf Rumensin® Gain to feed 
Calves Tylosin Morbidity 
 Tylan® Mortality 
 Implant Treatment 
 Steroid Implant Retreatment 
 TBA Abscess 
 Estradiol Liver abscess 
 Estrogen  
 Endectocide  
 Ivermectin  
 Fenbendazole  
 Pour-on  
 Parasiticide  
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Table 2:  The economic model assumptions used for the common breakeven inputs.  
Dollar amounts are in US dollars. 
Economic model 
assumptions 
Assumption 
In BW (kg) 250 
Laid in price ($/kg) $2.42 
Vaccination cost 
($/hd) 
$2.50 
Dewormer Cost 
($/hd) 
$1.60 
Feed Cost ($/909kg) $209.00 
Days on Feed 210 
Yardage/day $•hd-
1•d-1  
$0.30 
Interest rate 6.50% 
Out BW (kg) 568 
Shrink 4.00% 
Fat Cattle Price/kg $2.11 
 
Table 3:  The total number of studies used in the meta-analysis listed by the technology 
that was investigated. 
Technology Number of Studies Included 
Metaphylaxis 20 
Implanted 
Heifers 
9 
Implanted 
Steers 
44 
Monensin 6 
Tylosin 6 
Endectocides 8 
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Table 4:  Differences in least squares means ± SEM for Implants and Metaphylaxis from 
significant results in the mixed model 
Technology ADG (kg/day) Improved FE 
(gain:feed) 
DMI (kg/day) 
Metaphylaxis 0.11 ± 0.02*** --- --- 
Implanted Heifers 0.08 ± 0.04† 0.01 ± 0.003‡ --- 
Implanted Steers 0.25 ± 0.01*** 0.02 ± 0.001*** 0.53 ± 0.05*** 
‡ P= 0.14 
† P<0.10 
*** P<0.001 
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CHAPTER 3 - Characterization of Specific Passive Immunity 
Stimulated by Vaccination of Beef Cows Grazing Native Range with 
E. coli O157:H7-SRP®Abstract 
Abstract 
Twenty, four year old, mixed breed cows were selected from the Kansas State University 
commercial cow-calf herd for this study.  Cows were assigned randomly to one of two 
treatments, placebo or E. coli O157:H7 SRP®
a
 vaccination prior to calving.  Serum total protein 
(TP) and serum E. coli O157:H7 SRP® antibody levels (SRP) were measured pre-suckle and at 
set intervals post-suckle in calves.  All 20 cows were negative for fecal shedding of E. coli 
O157:H7 throughout the study.  Vaccination treatment that cows received had no effect on calf 
serum TP level (P > 0.05).  However, length of time post-birth had a significant effect on calf 
serum TP levels (P < 0.001).  Failure of passive transfer was recognized as early as 6 hours post-
birth.  There was a vaccine treatment by time post-birth interaction observed for calf serum SRP
®
 
antibody levels (P < 0.01).  Calves born to dams vaccinated with E. coli O157:H7 SRP
®
 vaccine 
had elevated serum SRP antibody titers over time compared to placebo vaccinated calves.  This 
study revealed that failure of passive transfer can be confirmed as early as 6 hours post-birth 
when colostrum supplements could still be administered.  Also, this study demonstrated that 
successful E. coli O157:H7 SRP
®
 antibody passive transfer can occur in beef calves under 
natural range conditions. This could be the first step of understanding lifecycle immunization 
strategies against E. coli O157:H7 in cattle and its effects on shedding of the organism by the 
animal at the point of harvest. 
Introduction  
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Calves are born agammaglobulinemic due to the separation of fetal and maternal blood 
flow that prevents the transfer of immunoglobulins from cow to fetus in utero.
2
  Following 
parturition the calf is reliant upon the immunoglobulins contained in the colostrum for protection 
from disease challenge during the first 2-4 weeks of life.
3
  Colostrum feeding has been reported 
as one of the most important management practices to prevent mortality during the first 21 days 
of a calf‟s life.22  Calves that fail to consume an adequate amount of colostrum within the first 
12-24 hours after birth are at a higher risk for disease, death and decreased performance.
23,24
  A 
number of studies have been performed examining the ability to passively transfer specific 
antibodies to beef calves, but none have examined E. coli O157:H7.
7,10,14,20
   
The epidemiology of E. coli O157 is not well understood and the prevalence of E. coli 
O157:H7 in cow-calf herds has not been thoroughly studied.  Some researchers have estimated 
the beef cattle herd level prevalence of E.coli O157:H7 to be 80-100%.
8,11,15,17  
However, 
individual animal level prevalence seems to be much lower, 2-18%.
8,11,15,16
  Designing the most 
effective E. coli O157:H7 control strategy will require knowledge of environmental risks and 
best management practices that have an impact on infection/colonization of the animal with E. 
coli O157:H7.  Currently the majority of control strategies for E. coli O157:H7 are aimed at the 
reduction of pathogen load at the feedyard level or post-harvest.
12,16
  Two studies utilizing beef 
cattle have suggested that initial infection of beef calves with E. coli O157:H7 may occur from 
their dams during the immediate post-natal period .
8,11
  Therefore, current control strategies that 
target the feedlot and harvest phases of the production system are combating a post-colonization 
issue.  A method to greatly lessen or eliminate the initial colonization of young beef calves 
would be a better food safety solution.   
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A new E. coli O157:H7 SRP
® 
vaccine has been issued conditional licensure for use in 
feedlot cattle in the United States.
5,19
  It is assumed that most circulating immunoglobulins will 
be concentrated in the colostrum of cattle.
9,13,21
  Therefore, the use of this vaccine with its unique 
epitopes and mode of action warrants further investigation into its ability to achieve passive 
transfer to possibly eliminate or decrease colonization of E. coli O157:H7 in beef cattle.  The 
objective of this study was to determine if E. coli O157:H7 SRP
®
 specific antibodies could be 
detected in the serum of calves that consumed colostrum from dams that were vaccinated before 
parturition with E. coli O157:H7 SRP
®
 vaccine. 
Materials and Methods 
General Overview 
In January of 2009, 20 cows were utilized from the Kansas State University commercial 
cow-calf herd to study the efficacy of passive transfer of specific E. coli O157:H7 SRP
®
 
antibodies in beef calves.  Four year old cows were selected, to control for parity and age, from 
the herd based on predicted calving dates and were balanced across pastures.  Cows were 
maintained on native dormant bluestem pasture and were supplemented 6 days per week with a 
soybean meal based supplement.  Cows were assigned randomly to one of two treatments: 
placebo or E. coli O157:H7 SRP
®
 vaccination.  Cows were vaccinated with their assigned 
vaccine treatments at 60 and 30 days prior to the projected start of the calving season.  Blood 
samples were collected from cows prior to the initial vaccination to ensure an E. coli O157:H7 
SRP
®
 antibody free status.  Serum ELISA‟s for detection of E. coli O157:H7 SRP® antibodies 
were conducted by Epitopix, LLC (Willmar, MN).  All laboratory personnel were blinded to 
treatment assignments.  At the time of calving, fecal, blood and colostrum samples were obtained 
from each cow and a pre-suckle blood sample was obtained from each calf.  Blood samples were 
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obtained from calves at 6, 12, and 24 hours and at 7, 14 and 21 days post-partum.  Serum total 
protein and E. coli O157:H7 SRP
®
 antibody concentrations were measured in all calves.   
 
Serology 
ELISA and Colostrum Assay 
Immulon-2 ELISA plates (Dynatech Laboratories) were coated with E. coli O157:H7 
SRP® antigen diluted in coating buffer (1.59 g/L Na2CO3, 2.93 g/L NaHCO3, pH 9.65).  One-
hundred (100) μl of the antigen solution was added to each well of the plate and allowed to 
incubate overnight at 4
o
C.  The coating antigen was then removed from the plate and replaced 
with 200μl blocking buffer (10g/L Poly Vinyl Alcohol, 1L 1xPBS).  The plates were then 
covered and incubated at 37
o
C for 1-2 hours.  The blocking buffer was then removed.  Serum 
from a calf that was hyper-immunized with the E. coli O157:H7 SRP® vaccine was used as a 
positive control.  The samples and control sera were then diluted to 1:100 in blocking buffer.  
Test sera were added to the first and 12
th
 well of the plate in duplicate and diluted 4-fold moving 
towards the center of the plate so that the last dilution achieved is 1:2400.  The plates were then 
covered and incubated at 37
o
C for one hour.  Plates were then washed three times with 0.05% 
Tween-PBS.  The conjugate (sheep anti-bovine IgG H&L HRP; The Binding Site, SanDiego, 
CA) was then diluted to 1:1600 in the blocking buffer plus 1% sheep sera.  One-hundred (100) μl 
of the conjugate solution was added to each well, and then the plate was covered and incubated 
at 37
o
C for one hour.  The plate was then washed three times with 0.05% Tween-PBS.  Pre-
warmed, two-component ABTS (Kirkegaard & Perry, Gaithersburg, MD) was combined and 100 
μl was added to each well of the plate.  The plate was incubated at room temperature until the 
optical density of the positive control wells was between 0.8 and 1.2.  Plates were then placed 
into the plate reader (BioTek ELx405; Winooski, VT) and read at 405/490nm and mixed prior to 
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reading.  The cut-off value for each series was calculated by multiplying the positive control by 
0.5 and plotting it against the sample dilution curves.  Sample titers were calculated based on the 
intersection of the cut-off line and the sample curves.  Sample titers were then reported as the 
reciprocal of the dilution at which the cut-off crosses the sample curve.  
 
Total Protein 
Blood was obtained from the jugular vein of each calf using 9 ml vacuum serum tubes 
(Greiner Bio-One NA) at each time point.  The blood was then allowed to clot while being 
refrigerated for 12-24 hours.  Samples were then centrifuged at 3500 RPM for 10 minutes to 
achieve serum separation from the clot.  Serum was then placed onto the refraction crystal of a 
commercially available, temperature compensated refractometer (Reichert; Depew, NY).  Total 
protein was read and recorded as g/dL. 
 
Fecal Culture 
Fecal samples were obtained directly from the rectum of each animal as it was restrained 
at each handling time point.  The samples were placed into collection vials and placed on ice.  
Samples were labeled with sequential numbers to blind treatment assignments.  Samples were 
then sent overnight to the Epitopix LLC testing laboratory.  Upon arrival at Epitopix, fecal 
samples were processed for isolation of E. coli O157 by immunomagnetic separation.  Samples 
were weighed and approximately 2 grams of each fecal specimen was placed into a Whirl-pak™ 
filter bag.  Gram-negative broth containing Cefixime (0.05 mg/L), Cefsulodin (10 mg/L) and 
Vancomycin (8 mg/L)  (GNccv) was used to get the fecal specimen in a liquid state for sample 
processing.  Samples were normalized by weight so each sample was present at a ratio of 1 gram 
feces per 10 mls of GNccv broth.  Samples were incubated at 37°C overnight for enrichment of 
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E. coli O157.  Following enrichment, 1 ml of each sample was added to a 96-well plate 
containing 20 µl of magnetic Anti-O157 Dynabeads (Invitrogen, Carlsbad, CA).  The enriched 
cultures were allowed to incubate with the magnetic beads on a shaker at room temperature for at 
least 15 minutes per the manufacturer‟s directions.  Magnetic particles were recovered and 
washed using an 8-channel magnetic PikPen (Bio-Nobile, Turku, Finland).  After the final wash, 
the particles were released into 100 µl of wash buffer (PBS containing 0.05% Tween20) in a 96-
well plate for plating of E. coli O157 that was bound to the magnetic particles.  For plating, 50 µl 
was plated onto a Sorbitol MacConkey agar plate containing Cefixime and Tellurite (CT-SMAC) 
(Becton Dickinson, Franklin Lakes, NJ) and 50 µl was plated onto a Chromagar-O157 plate 
(Chromagar, Paris France).  The inoculum was spread onto each agar plate and the plates were 
incubated at 37°C overnight.  The plates were observed for suspect E. coli O157 colonies which 
were then tested for O157 agglutination using an O157 test kit from Remel (Lenexa, KS) per the 
manufacturer‟s instructions.  Positive samples were sub-cultured to Chromagar-O157 or CT-
SMAC to acquire a pure culture of E. coli O157.   
Vaccine Preparation 
The commercially available E. coli O157:H7 SRP
® 
vaccine was prepared in the same 
manner as reported previously.
6,18,19
  The placebo vaccine contained phosphate-buffered saline 
emulsified with the same commercial adjuvant (Emulsigen, MVP Laboratories, Ralston, NE) 
used in the vaccine.  Vaccine and placebo bottles were marked A or B to blind the vaccine 
administrator to the treatments.  Each cow received 2ml of the corresponding vaccine 
subcutaneously in the neck following Beef Quality Assurance guidelines
4
. 
 
Data Analysis 
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Data were recorded and summarized using the Excel (Microsoft; Redmond, WA) 
program.  ELISA results were transformed using a log base 2 function prior to using the data for 
statistical analysis.  The individual calf served as the experimental unit. Data were analyzed 
using the wsanova procedure in STATA
®
 (College Station, TX) for repeated measures of an 
individual.  Cow vaccination treatment, pasture, cow ELISA at the time of calving, calf ELISA, 
time and their interactions were all presented as possible variables for the model.  Colostrum 
endpoint ELISA data was analyzed using a generalized linear model using a Gaussian 
distribution and identity link function.   P-values ≤ 0.05 were considered significant.  
 
Results and Discussion 
None of the cows required assistance during parturition and all calves nursed within 2 
hours after birth without assistance.  Vaccination treatment had no effect on the calf serum total 
protein (TP) level (P > 0.05).  However, the length of time post-birth had a significant effect on 
calf serum TP levels (P < 0.001) (Figure 3.1).  This is an expected finding given that calves are 
born agammaglobulinemic until absorption of maternal antibodies from colostrum.
2
  One calf in 
the study was classified as having failure of passive transfer (TP level < 5.5 g/dL at 24 hours).  
This resulted in a 5% failure of passive transfer prevalence which would be consistent with other 
reported prevalence estimates in beef cattle, yet well below that of many dairy estimates.
13,21
  
The calf which exhibited failure of passive transfer was born to a cow that had very little udder 
development and milk production at the time of parturition which was likely the main factor for 
failure of passive transfer.  There was a vaccine treatment by time post-birth interaction observed 
for the calf serum E. coli O157:H7 SRP
®
 antibody levels (P < 0.01, Figure 3.2).  This interaction 
was explained by no vaccine treatment difference in calf serum E. coli O157:H7 SRP
®
 antibody 
levels pre-suckle but a significant increase in calf E. coli O157:H7 SRP post-suckle titers in the 
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calves born to SRP
®
 vaccinated cows compared to calves born to cows that received the placebo 
vaccination.   
Of the 20 cows enrolled in the study only 19 colostrum samples were collected and 
analyzed.  The average endpoint E. coli O157:H7 SRP
®
 antibody titers were different between 
the two treatments (P < 0.001) at 150 and 16,835 for placebo and vaccinated cows, respectively 
(Figure 3.3).  Natural range assignment was not a significant factor for antibody titer level of 
either treatment (P > 0.70).  This marked difference for antibody titers, between vaccinated and 
placebo cow‟s colostrum, is in agreement with earlier work done examining E. coli K99 vaccine 
efficacy and protection in neonatal calves.
 1
   
Another observation from this study was the length of time post-parturition in which 
calves achieved adequate passive transfer.  The majority of the calves achieved adequate passive 
transfer (TP = 5.5 g/dL) by 6 hours post-parturition (Figure 3.1).  These TP levels were achieved 
in spite of increased handling of cows and calves immediately after parturition due to 
experimental conditions.  These data suggest that the passive transfer status of neonatal calves 
may be accurately assessed prior to partial gut closure at 12 hours, and full closure at 24 hours.
 21
  
This may be a useful strategy for producers to employ when operating an aggressive colostrum 
management program.   
All 20 cows were negative for fecal shedding of E. coli O157:H7 at all three sampling 
times.  These data do not correspond to previous findings for fecal prevalence of beef cow-calf 
E. coli O157:H7 which reported individual animal level prevalence ranging from 2 to 18% and a 
herd level prevalence ranging from 87 to 100%.
8,11,15,17
  The current study did not employ a true 
random sample of the herd that would be required to truly establish the herd prevalence.  The 
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focus of the current study was colostrum quality and composition, and E. coli O157:H7 
prevalence was secondary.  Therefore, investigators controlled parity to decrease variation in 
colostrum quality between cows of different parity.  Selection bias could have been inadvertently 
introduced to this study if 4 year old cows are at a lower risk for shedding E. coli O157:H7 than 
other cows in the herd.  Previous studies have reported a greater chance of isolating E.coli 
O157:H7 through repeated sampling.
17
  Some researchers have reported that beef cows may not  
detectably shed E. coli O157:H7 prior to parturition but will shed this foodborne pathogen within 
one week after parturition.
8
  The third and last sampling of cows in this study occurred 
immediately after parturition and yet no cows were found to be shedding E. coli O157:H7.  The 
exact onset of shedding and the factors related to the induction of shedding warrant further 
investigation. 
This study documented the speed at which passive transfer can occur in beef cattle 
following parturition.  Calves were observed to have successful passive transfer in the first 6 
hours after birth.  This knowledge could be used by producers in situations where the colostrum 
intake is unknown or the calf is of high value.  A producer or veterinarian could identify passive 
transfer failures prior to significant gut closure and intervene with colostrum support.  This is 
also the first report of successful E. coli O157:H7 SRP
®
 antibody passive transfer in beef calves 
under natural range conditions.  These data provide information for further study into possible 
cross protection of this vaccine against neonatal E. coli diarrhea strains such as K99.  This 
research is the first step of understanding lifecycle immunization strategies against E. coli 
O157:H7 in cattle and its effects on shedding of the organism by the animal at the point of 
harvest. 
Endnotes 
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a
SRP® is a trademark of Epitopix LLC (Willmar, MN) that stands for siderophore 
receptor and porin proteins 
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Figure 3.1: Average total protein of calves in the vaccination (squares) and placebo 
(diamonds) treatment groups at pre-suckle, and 6, 12, 24 hours post-suckle.  Error bars signify 
the standard deviation for the measurements at the given time point. 
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Figure 3.2:  Average E. coli O157:H7 SRP® antibody of calves in the vaccination 
(squares) and placebo (diamonds) treatment groups at pre-suckle 6, 12, and 24 hrs and 7, 14 and 
21 days post-suckle.  Error bars signify the standard deviation for the measurements at the given 
time point. 
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Figure 3.3:  Average endpoint E. coli O157:H7 SRP® antibody titers of colostral samples by 
vaccination and placebo treatment groups.  Error bars represent the standard deviation. 
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CHAPTER 4 - Passive Immunity of Neonatal Calves Given 
Colostrum Containing Escherichia coli O157:H7 SRP Antibodies to 
an Escherichia coli K99 Challenge 
Introduction 
Neonatal calf diarrhea is one of the leading causes of morbidity and mortality in calves 
(Combs et al. 1993).  The most commonly described causative agents of acute neonatal diarrhea 
(scours) are Escherichia coli, coronavirus, rotavirus, and Cryptosporidium.  E. coli strains that 
are K99 positive have been responsible for an estimated 25-30% of the scours cases in calves in 
the first 3-4 days after birth (Acres 1985; Holland 1990; Naylor 2002).  E. coli K99 positive 
organisms have been responsible for 30-50% of the scours-related deaths in neonatal calves 
(Acres 1985; Combs et al. 1993). 
Calves are born agammaglobulinemic due to the separation of fetal and maternal blood 
flow that prevents the transfer of immunoglobulins from cow to fetus in utero (Arthur et al. 
1996).  As a result the calf is reliant upon the immunoglobulins contained in the colostrum for its 
protection from disease challenge in the first 2-4 weeks of life (Barrington & Parrish 2001).
  
Therefore, passively derived antibodies from colostrum are an important component in the calf‟s 
ability to defend itself from pathogens.  Colostrum feeding management protocols have been 
reported as a leading cause of mortality in the first 21 days of a calf‟s life (Wells et al. 1996).   
The ability to protect a calf through colostrum derived antibodies has been studied for 
many years.  Protection afforded to neonatal calves by colostrum containing E. coli K99 specific 
antibodies has been previously reported (Combs et al. 1993; Acres et al. 1979; Eichhorn et al. 
1982; Gouet et al. 1978; Nagy 1980; Riedel-Caspari 1993; Snodgrass et al. 1982; Valente et al. 
1988).  These studies have illustrated the wide range of morbidity and mortality outcomes 
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possible with E. coli K99 challenge in both controlled and field conditions.  Morbidity and 
mortality estimates, across studies, range from 0-100% with an average morbidity and mortality 
rate of 63% and 33%, respectively. 
All of these studies used E. coli K99 specific colostral antibodies derived from 
vaccinating the cows with an E. coli K99 derived vaccine.  Recently an E. coli O157:H7 SRP
® 
vaccine for cattle was granted licensure by the USDA.  The unique mechanism of action of this 
vaccine makes it a candidate for further study of uses in the cattle industries.  The efficacy of this 
vaccine has been demonstrated to reduce fecal shedding of E. coli O157:H7 under experimental 
and field conditions (Fox et al 2009; Thomson et al. 2009; Thornton et al. 2009) and also passive 
immunity under field conditions (Wileman et al. 2010).  To date there have been no studies 
reported that have examined the possibility of cross protection of E. coli O157:H7 against E. coli 
K99 challenge.  The goal of this study is to examine the degree of cross protection provided by 
colostrum containing a known amount of E. coli O157:H7 antibodies against an oral challenge of 
E. coli K99 as evidenced by morbidity effects in neonatal colostrum deprived calves. 
 
Methods & Materials 
General Overview 
This protocol and project was approved by the Kansas State University Institutional 
Animal Care and Use Committee.  Eleven neonatal, colostrum deprived male Holstein calves 
were obtained from a local dairy calving facility and transported to a climate controlled research 
facility in Willmar, MN.  Prior to their procurement, calves were randomly assigned to one of 
two treatment groups: 1) colostrum from non-vaccinated heifers or 2) colostrum from heifers 
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vaccinated with SRP E. coli O157:H7 vaccine prior to calving.  Each calf was uniquely 
identified via individually numbered ear tags placed in the ear at the time of arrival to the 
research facility.  Calves were individually housed on sawdust bedding with a separate footbath 
assigned to each pen to prevent cross contamination during husbandry and scoring procedures.  
Calves were administered the E. coli challenge strain orally one hour after colostrum treatment 
administration.  Calves were observed twice a day (day 0-7) and a hydration (0 or 1), fecal (1-4), 
respiratory (1-3) and an appetite score (1-3) was recorded.  Upon completion of the study all 
surviving calves were maintained at the research facility until all clinical signs of diarrhea were 
resolved with no recurrence for 72 hours and then were sold to a commercial calf raiser. 
Colostrum Preparation 
Prior to initiation of the study, dairy heifers were vaccinated three times with E.coli 
O157:H7 SRP
®
 at 90, 60 and 30 days prior to parturition and the colostrum from these heifers 
was collected. The colostrum was pooled and placed into 3 quart aliquots and labeled (SRP 
colostrum).  Colostrum was also collected from non-vaccinated heifers, pooled and placed in 3 
quart aliquots (control colostrum).  For blinding study personnel, the final bags of colostrum that 
were administered to the calves were labeled A or B, corresponding to dam vaccination status.  
Calves were administered the colostrum via esophageal tube one hour prior to challenge. 
Observation and Sampling 
Each calf was assessed and a score was recorded for hydration, fecal consistency, rectal 
temperature and appetite upon arrival to the research facility, one hour post-challenge and twice 
daily thereafter.  All animal caretakers and scoring individuals were blinded as to the assigned 
treatment group of each calf.  Blood was collected prior to colostrum administration and then 
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every 24 hours thereafter until completion of the study (day 7) for measurement of E. coli 
O157:H7 specific SRP antibody to monitor passive transfer of maternal antibodies.  Hydration 
was assessed on all calves daily via visual observation and a skin tent test.  A binomial hydration 
score of 0 was given for normally hydrated calves, eyes bright with pliable skin or 1 having 
dehydration, eyes dull or sunken and loss of skin pliability.  Fecal consistency was scored twice 
daily with the following scores: 1 (normal consistency, firm & well formed), 2 (mild diarrhea, 
softer than normal but not runny), 3 (moderate diarrhea, runny but some texture), and 4 (having 
severe diarrhea where the feces was very runny with very little texture).  Rectal temperatures 
were taken via digital thermometer and recorded twice daily.  Appetite was scored on a three 
point scale with 1 indicating a normal appetite, 2 indicating a slightly depressed appetite and 3 
indicated inappetence.  And respiration was scored by 1 (normal respiratory effort), 2 (mild 
increase in respiratory effort) and 3 (labored respiratory effort). An approximately 2 gram fresh, 
fecal sample was obtained on arrival to the research facility and then once daily for culture of the 
E. coli K99+ challenge organism. 
Challenge Strain 
Five hundred ml of pre-warmed (37
o
C) Tryptic Soy Broth (TSB) (Becton Dickinson, 
Franklin Lakes, NJ) containing 20g/ml of dipyridyl (Sigma, St. Louis, MO) and 100g/ml of 
nalidixic acid (Sigma, St. Louis MO) were inoculated with 5l of K99 E. coli strain 1126.  The 
bottle was incubated on a shaker at 37
o
C for 13.5 hours.  Twenty-Five (25) ml of the culture 
were then passed into eight bottles containing ~1,350 ml of the same media.  The bottles were 
then incubated on a shaker at 37
o
C until an OD545 was between 1.1 and 1.4 (4 hours).  The 
culture was then harvested by centrifugation using a Beckman JA-10 rotor at 6,000 RPM for 20 
minutes.  The supernatant was discarded and the pellets were re-suspended until a 1:1,000 
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dilution in TSB yielded an OD545 of 0.3.  Ten ml of this suspension were added to 35 ml of saline 
which served as 1 calf dose and was given to each calf via an esophageal tube.  The titer of the 
culture was determined by performing 10-fold dilutions of the culture in saline, plating the 
dilutions on blood agar plates, incubating and counting colonies.  The titer was checked for each 
challenge preparation before and after challenge.  The titer of the challenge dose per calf was 1 x 
10
11
 CFU of E. coli K99. 
Serology 
Serum antibody response was determined by enzyme-linked immunosorbant assay 
(ELISA).  E. coli O157 SRP antigen was coated on Nunc Maxisorp 96 well plate (Nalge Nunc 
International  Rochester, NY) at 250ng/well in Carbonate Coating Buffer (pH 9.6), covered and 
incubated overnight at 4°C.  Plates were then dumped and blocked using 1% PVA/PBS, covered 
and incubated at 37°C for one hour.  Dilutions of the serum samples were prepared in 1% 
PVA/PBS at 1:100 and then serially four-fold diluted.  Plates were then covered and incubated at 
37°C for one hour.  The plate was then washed three times with 0.05% PBS-Tween 20.  
Following the wash step a 1:1600 dilution of the conjugate, HRP sheep anti-bovine IgG (The 
Binding Site  San Diego, CA), in 1% PVA/PBS was applied to the plate, covered, and incubated 
at 37°C for one hour.  The wash step from above was repeated prior to development with  2,2‟ 
azino-di-3-ethyl-benzthiazoline-6-sulfonate (ABTS) (KPL, Inc.  Gaithersburg, MD).  The 
absorbance of the wells was then read at 405-490nm using an ELISA reader.  Using the optical 
density values of the Positive control, a cut-off line was calculated by multiplying the mean of 
the positive control by 50%.  The optical density and dilution data of the samples was then 
graphed and the cut-off line was applied.  The sample titers were calculated based on where the 
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cut-off line (PC) intersected the sample curves.  The sample titer was reported as the reciprocal 
of the dilution at which the cut-off (PC) crosses the sample curve. 
 
E. coli K99 Culture  
The presence and concentration of the E. coli K99 challenge strain was determined by 
plating the fecal samples on Eosin Methylene-Blue (EMB) agar (EMD  Gibbstown, NJ) 
containing 100µg/ml Nalidixic acid (Sigma  St. Louis, MO).  Briefly, for each sample, 
approximately 2 grams of fecal material was mixed with 20ml Tryptic Soy  Broth (BD  Sparks, 
MD) with 100µg/ml Nalidixic acid in a filter bag.  One milliliter of the filtrate was removed and 
diluted out to 10
-5 
and plated.  The remaining fecal suspension was incubated at 37°C overnight, 
and then plated.  The Nalidixic acid resistant challenge strain colonies present on the titration 
plates were counted, and the enrichment plates were documented as positive or negative for 
growth of the challenge strain. 
Data Analysis 
All observations and clinical scores were recorded on a standard observation sheet for 
each calf.  Scores were transcribed from the written forms to an Excel
®
 spreadsheet for data 
manipulation and reporting of descriptive statistics.  Data were statistically analyzed in STATA
®
 
using linear regression and ordered logistic regression models with treatment, day of study and 
their interactions submitted as predictors. 
Results 
A total of five calves died prior to study termination from causes unrelated (clinical signs 
or death prior to administration of challenge dose) to E. coli K99 challenge (3 from SRP group, 2 
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from control group).  Colostrum treatment assignment had no significant effect on rectal 
temperature, attitude, respiratory, or hydration scores of calves (P > 0.05).  Day of challenge was 
significantly predictive of rectal temperature, attitude, respiratory, and hydration scores of calves 
(P < 0.05).  There were no significant day by colostrum treatment interactions for any of the 
parameters (P > 0.05).  SRP colostrum treated calves had significantly improved fecal scores 
compared to control calves (P = 0.05; Figure 4.1).   Colostrum treatment had no effect on 
elimination of fecal shedding of E. coli K99 by calves (P > 0.05).  However, SRP colostrum 
treated calves had a 0.45 log CFU/ml lower concentration of E. coli K99 in feces (P = 0.05; 
Figure 4.2).  Control colostrum calves had significantly lower serum E. coli O157:H7 SRP 
antibodies than SRP colostrum treated calves (P < 0.001; Figure 4.3). 
Discussion 
The death loss incurred at the beginning of the study severely limited the statistical power 
of this trial to detect differences between treatment groups.  The use of an E. coli O157:H7 
vaccine pre-partum has largely been unstudied as to its ability to protect the calf from E. coli 
O157 infection/colonization and its ability to cross-protect against other pathogenic species such 
as K99.  This is the first report using this approach.  In spite of very limited statistical power 
there does appear to be encouraging results in a significant improvement in fecal consistency 
(Figure 4.1), reduction in concentration of shedding of challenge organism (Figure 4.2) and a 
strong antibody response (Figure 4.3).   
The experimental efficacy of vaccines administered to cows prior to calving and the 
subsequent protection of the calf post-colostral intake has been reported in the literature 
extensively (Jayappa et al. 2008; Crouch et al. 2001; Combs et al. 1993; Eichhorn et al. 1982).   
However few studies go into the field and examine the “field efficacy” of this management 
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procedure while controlling for other management issues.  In a large observational study Trotz-
Williams et al. (2007) found a significant reduction in the likelihood (OR 0.58 95% CI 0.41-
0.81) of a calf being diagnosed with diarrhea when it was born to a dam previously vaccinated 
with a vaccine containing E. coli antigens.  In that study enterotoxigenic E. coli isolates were 
present in 51% of all of the fecal samples.  Interestingly, they also reported a significantly 
increased likelihood of diarrhea in calves born during the summer rather than the winter which is 
in contrast to other reports (Waltner-Toews et al. 1986; Frank and Kaneene 1993).  The current 
study was conducted in Minnesota during the month of January.  Although the calves were 
housed in controlled conditions during the study, prior to their procurement they were born and 
retrieved from maternity pens in hoop-barns, placed into a warm calf shed, and then transported 
one hour to the research facility.  In the author‟s opinion the early morbidity and mortality that 
was unrelated to the trial was largely due to affects of hypoxia/hypothermia as all calves were 
necropsied with no lesions found indicating disease or calving trauma (data not shown) and 
clinical signs (if present) were present prior to challenge dose administration. 
Escherichia coli O157:H7 from which the vaccine used in the current trial was created 
has been shown to be virulent to neonatal calves capable of producing morbidity and even 
mortality (Dean-Nystrom et al. 1997).  In a field study, calves with clinical diarrhea that were 
two weeks old or younger had an E. coli O157:H7 prevalence of 15.8% whereas the clinically 
normal calves had 0% prevalence (Kang et al. 2004).  This was a small power study performed 
in South Korea so the production practices related to the U.S. is unknown, but does allude to E. 
coli O157:H7 as being a possible cause of neonatal diarrhea.  The current study did not attempt 
to examine the fecal samples for E. coli O157 as the K99 isolates are much more common in 
reported field isolates (Holland 1990; Naylor 2002; Trotz-Williams et al. 2007). 
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This trial confirms the findings of Wileman et al. (2010) of successful passive transfer of 
E. coli O157:H7 SRP specific antibodies in calves.  The field trial used beef breed calves housed 
under natural range conditions whereas the present trial utilized dairy breed animals administered 
colostrum via an esophageal tube feeder.  In a recent study Godden et al (2009) reported an 
interaction between the amount of colostrum fed (1.5L vs 3.0L) and the method it was delivered 
(esophageal feeder vs nipple) on serum total protein (TP) and IgG concentrations.  There was no 
difference in serum TP or IgG between calves fed 3.0 L of colostrum with a nipple or an 
esophageal feeder.  However, calves fed 1.5 L of colostrum via nipple had improved apparent 
efficiency of absorption of IgG over calves fed via esophageal tube.  In the present study the 
calves were administered approximately 2.8 L of colostrum via esophageal tube and the resulting 
serum ELISA titers of antibodies to E. coli O157:H7 SRP group calves were very similar to 
those reported by Wileman et al (2010) for beef calves consuming colostrum under natural 
conditions.   
Due to the encouraging results, further study is warranted into the use of the E. coli 
O157:H7 SRP vaccine pre-partum through the refinement and repetition of this trial during a 
warmer period of the year with stricter enrollment criteria and additional isolation procedures for 
E. coli O157:H7 organisms in fecal samples.  It does appear that vaccination of cows pre-partum 
with E. coli O157:H7 SRP vaccine may provide additional benefits against clinical signs and 
shedding of pathogenic E. coli K99 in calves through passive immunity.  Decreased shedding of 
E. coli K99 into the immediate neonatal environment would decrease the likelihood of large 
neonatal diarrhea outbreaks in intensive systems.  Further study into the cross-protective ability 
of the E. coli O157:H7 SRP vaccine against K99 and other pathogenic strains of E. coli is 
needed. 
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Figure 4.1: Average fecal consistency score of calves (1=Normal, 2= Mild, 3=Moderate, 
4=Severe) by day of observation.  SRP colostrum had improved fecal consistency scores 
compared to control calves (P = 0.05).  
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Figure 4.2: Fecal E. coli K99 concentration (log10 CFU/ml) by day of study.  SRP 
colostrum calves had lower concentrations of E. coli K99 shed in feces compared to 
control calves (P = 0.05). 
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Figure 4.3: Serum Anti-E. coli O157:H7 SRP Antibody (log2) by day of study.  
Error bars represent the standard deviation of the titer at each time point.  SRP 
colostrum calves had increased anti-E. coli O157:H7 titers compared to control 
calves (P < 0.001).  
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CHAPTER 5 - Escherichia coli O157:H7 Shedding in Beef Calves 
Vaccinated with Escherichia coli O157:H7 SRP
®
 Vaccine Born to 
Cows Vaccinated Pre-partum with Escherichia coli O157:H7 SRP
®
 
Vaccine  
Introduction 
Enterohemorrhagic Escherchia coli 0157:H7 is one of the most recognized human, 
foodborne pathogens in the United States and around the world.  E. coli was first recognized as a 
human foodborne pathogen in the early 1980‟s after two outbreaks linked to undercooked 
hamburgers (Riley et al. 1983).  There are three manifestations of infections in humans:  
hemorrhagic colitis, hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic 
purpura (TTP) (Griffin & Tauxe 1991).  Signs of human infection occur 3-5 days after ingestion 
of the organism.  Most cases are self limiting in that only 5% of cases result in the severe 
complications of HUS or TTP (Bach et al. 2002).  The groups of people most at risk of 
developing the severe complications are children under the age of 5 years old, the elderly and 
immunocompromised individuals.  The largest numbers of reported cases are in the countries of 
the United States, Canada and the United Kingdom (Griffin & Tauxe 1991).  The 2006 reported 
incidence of E. coli 0157 infections in the U.S. by the Center for Disease Control‟s FoodNet was 
1.31 per 100,000 which is half of what the incidence was just 10 years prior.  Much of the 
decrease is likely related to peri- and postharvest intervention strategies implemented through the 
hazard analysis and critical control points (HACCP) system in all FDA regulated harvest 
facilities.  
A major development in the ecology and epidemiology of E. coli O157 was the 
establishment of cattle as the reservoir for E. coli O157:H7 (Riley et al. 1983).  This spurred a 
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large amount of research focused specifically on E.coli 0157:H7 and its involvement with beef 
cattle.  Early prevalence estimates estimated the herd level prevalence of E. coli O157 to be 
around 8-16% (Bach et al. 2002).  The development of more sensitive testing procedures such as 
immunomagnetic separation (IMS) has increased the sensitivity of detection of the organism by 
10-100 fold (Chapman et al. 1994).    This has resulted in more accurate and increased estimates 
of the true prevalence of E. coli O157:H7 in the U.S. beef herd.  A study by Elder et al. (2000) 
found a feedlot-level prevalence of 63% and an individual animal-level prevalence of 
approximately 28%.  The prevalence of E. coli O157 is affected by season, the testing frequency 
and timing of sampling and the treatment of the samples prior to isolation, and the geographic 
location (Bach et al 2002; Rhoades et al. 2009).  In the U.S., the summer months of May through 
September tend to have the highest prevalence estimates of E. coli O157:H7 in cattle feces with 
the winter months having the lowest prevalence (Van Donkersgoed et al. 1999).   
There are a number of pre-harvest intervention strategies that have been reported.  In two 
separate reviews of pre-harvest control of E. coli O157:H7, the reviewing authors found that the 
probiotic containing Lactobacillus acidophilus NP51 and P. freudenreichii was the only 
intervention strategy that has been significantly and consistently proven in field trials to increase 
animal resistance to infection with E. coli O157 (Sargeant et al. 2007; Lejune &Wetzel 2007).  
Sargeant et al. (2007) also concluded that sodium chlorate in the feed or water also increased 
animal resistance to infection with E. coli O157 even though it has not been labeled for use in the 
U.S.  Neither of the reviews considered the vaccine technology utilizing E. coli O157:H7 SRP
®
, 
for controlling E. coli prevalence in cattle pre-harvest.  This technology has recently received 
conditional licensure in the U.S. and has been extensively studied for control of E. coli 
prevalence and concentration in feeder cattle feces (Fox et al. 2009; Thomson et al. 2009; 
 104 
Thornton et al. 2009; Wileman et al. 2010).  The majority of existing research and control 
strategies attempt to control E. coli O157 at the feedyard and harvest stages of production.  These 
approaches are addressing the problem post-colonization.  The objectives of this study were to 
determine the shedding characteristics, health and performance of E.coli O157:H7 SRP 
throughout the lifetime of beef calves born to E.coli O157:H7 SRP vaccinated dams verses 
unvaccinated dams.  Also, this study examined the effects of a series of E. coli O157:H7 SRP 
vaccinations in beef calves prior to and at the time of arrival at the beef finishing facility had on 
the E. coli O157:H7 shedding characteristics, health and performance throughout their lifetime. 
Materials and Methods 
General Overview 
This study was conducted under conditions approved by the Kansas State University 
Institutional Animal Care and Use Committee.  In January of 2009, 437 cows from the Kansas 
State University two commercial cow-calf herds were stratified by age and randomly assigned to 
either E. coli SRP vaccine or placebo treatment groups.  Blood samples were collected from 
cows prior to the initial vaccination to ensure an E. coli O157:H7 SRP
®
 antibody free status.  
Cows were vaccinated with their assigned vaccine treatments at 60 and 30 days prior to the 
projected start of the calving season.  To create a 2X2 factorial treatment structure, calves were 
then blocked by dam treatment and randomly assigned to E. coli SRP vaccine or placebo 
treatment groups which were administered at branding, preconditioning and entry to the feedlot.  
Therefore, there were a total of four treatments in this study: 1) neither cows nor calves 
vaccinated with E. coli O157:H7 SRP (CON), 2) cows vaccinated with E. coli O157:H7 SRP 
technology pre-partum but calves not vaccinated (COWVAC), 3) calves vaccinated with E. coli 
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O157:H7 SRP technology born to cows not vaccinated (CALFVAC), 4) cows vaccinated with E. 
coli O157:H7 SRP technology pre-partum and calves also vaccinated (BOTH).  The two vaccine 
treatments were prepared by the sponsoring company and labeled A & B to blind study 
personnel.  Also, all blood and fecal samples were labeled with sequential numbers to blind 
laboratory personnel.   
Cows and calves were managed according to normal ranch management conditions at 
each unit throughout the study.  While on pasture cows & calves from the four treatment groups 
were allowed to commingle i.e. vaccinates with placebo.  During the preconditioning and feedlot 
phases of the trial, calves were penned according to sex and vaccine treatment group.  A 30 day 
ranch preconditioning trial was also conducted and balanced across the current trial‟s treatment 
groups.  Calves were gathered while on grass at the traditional branding time age of 
approximately 90 days old.  Calves were given a 7-way Clostridial vaccine and their first 
assigned SRP vaccine treatment, had blood and fecal samples collected, and the males were 
castrated.  Calves were returned to their dams and turned out to grass pastures until weaning.  
Calves were abruptly weaned and transported to preconditioning pens at each of the two ranches 
where they were processed, administered the second dose of SRP vaccine and provided ad 
libitum access to fresh grass hay and water.  At the end of the 30 day preconditioning period 
calves were transported by truck 3 hours to an auction facility where they remained overnight, 
and then were reloaded and transported to the feedyard.  Calves were processed on arrival to the 
feedyard and administered their third and final SRP vaccine dose if assigned to that treatment.  
Feedlot pens were created by combining a matched (matched by sex and treatment assignment) 
preconditioning pen from each of the two ranches.  Calves remained in these pens for the 
remainder of the study.  Health and performance data were collected monthly.   
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Serology 
Serum antibody response was determined by enzyme-linked immunosorbant assay 
(ELISA).  E. coli O157 SRP antigen was coated on Nunc Maxisorp 96 well plate (Nalge Nunc 
International Rochester, NY) at 250ng/well in Carbonate Coating Buffer (pH 9.6), covered and 
incubated overnight at 4°C.  Plates were then dumped and blocked using 1% PVA/PBS, covered 
and incubated at 37°C for one hour.  Dilutions of the serum samples were prepared in 1% 
PVA/PBS at 1:500 in duplicate. Plates were then covered and incubated at 37°C for one hour.  
The plate was then washed three times with 0.05% PBS-Tween 20.  Following the wash step a 
1:1600 dilution of the conjugate, HRP sheep anti-bovine IgG (The Binding Site  San Diego, CA), 
in 1% PVA/PBS was applied to the plate, covered, and incubated at 37°C for one hour.  The 
wash step from above was repeated prior to development with 2,2‟ azino-di-3-ethyl-
benzthiazoline-6-sulfonate (ABTS) (KPL, Inc.  Gaithersburg, MD).  The absorbance of the wells 
was then read at 405-490nm using an ELISA reader.  The average of the negative controls‟ 
optical density was calculated and subtracted from all values as a reagent blank.  Then the 
sample duplicates were averaged and divided by the positive control average yielding the sample 
to positive (S:P) titer. 
Fecal Culture 
Fecal samples were obtained directly from the rectum of each animal as it was restrained 
at each handling time point.  The samples were placed into collection vials and placed on ice.  
Samples were labeled with sequential numbers to blind treatment assignments and were sent 
overnight to the Epitopix LLC testing laboratory.  Upon arrival at Epitopix, fecal samples were 
processed for isolation of E. coli O157 by immunomagnetic separation.  The same procedure 
previously described by Wileman et al. (2010) was used for the branding, preconditiong and 
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feedlot arrival samples.  The simulated slaughter fecal samples used the same procedure except 
samples underwent a six hour enrichment rather than overnight.  Briefly, samples were weighed 
and approximately 2 grams of each fecal specimen was placed into a Whirl-pak™ filter bag.  
Gram-negative broth (GNccv) was used to get the fecal specimen in a liquid state for sample 
processing.  Samples were normalized by weight so each sample was present at a ratio of 1 gram 
feces per 10 mls of GNccv broth.  Samples were incubated at 37°C overnight (6 hours for 
simulated slaughter samples) for enrichment of E. coli O157.  Following enrichment, 1 ml of 
each sample was added to a 96-well plate containing 20 µl of magnetic Anti-O157 Dynabeads 
(Invitrogen, Carlsbad, CA).  The enriched cultures were allowed to incubate with the magnetic 
beads on a shaker at room temperature for at least 15 minutes.  Magnetic particles were 
recovered and washed using an 8-channel magnetic PikPen (Bio-Nobile, Turku, Finland).  After 
the final wash, the particles were released into 100 µl of wash buffer (PBS containing 0.05% 
Tween20) in a 96-well plate for plating of E. coli O157 that was bound to the magnetic particles.  
For plating, 50 µl was plated onto a Sorbitol MacConkey agar plate containing Cefixime and 
Tellurite (CT-SMAC) (Becton Dickinson, Franklin Lakes, NJ) and 50 µl was plated onto a 
Chromagar-O157 plate (Chromagar, Paris France).  The inoculum was spread onto each agar 
plate and the plates were incubated at 37°C overnight.  The plates were observed for suspect E. 
coli O157 colonies which were then tested for O157 agglutination using an O157 test kit from 
Remel (Lenexa, KS).  Positive samples were sub-cultured to Chromagar-O157 or CT-SMAC to 
acquire a pure culture of E. coli O157.   
Data Analysis 
Data were recorded and summarized using the Excel (Microsoft; Redmond, WA) 
program.  For feed efficiency (FE) and dry matter intake (DMI) the pen was the experimental 
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unit, for all other factors the calf was the experimental unit.  The majority of the heifers enrolled 
in this study were placed onto a heifer development trial therefore only data from steers and cull 
heifers destined for slaughter (n = 252) were used for the reported feedlot entry and slaughter 
statistics.  Data were statistically analyzed using GLIMMIX and Mixed procedures in SAS
®
 9.1 
(SAS Institute Inc.; Cary , NC).  Lung lesions, liver abscess, morbidity and mortality data was 
given a binomial score, summarized and modeled using an events/trial format with feedlot pen as 
a random effect using the GLIMMIX procedure.  Model adjusted risk probabilities were then 
calculated for these outcomes.  Cow vaccination, calf vaccination, ranch of origin, 
preconditioning trial treatment and their interactions were presented as possible variables in each 
model.  P-values ≤ 0.05 were considered significant. 
Results 
The final number of cattle in each treatment group was 105 CON, 103 CALFVAC, 100 
COWVAC and 108 BOTH for a total of 416 head.  None of the calves were found to be 
shedding E. coli O157 on fecal cultures at the time of initial vaccination at branding.  Calves 
born to vaccinated cows had significantly increased titers of anti-E. coli O157:H7 SRP 
antibodies (SRPAb) in circulation at branding (P < 0.001).  Only three calves were shedding E. 
coli O157 at weaning, and all three were placebo calves.  At weaning calves from ranch number 
one had significantly greater SRPAb titers than did calves from ranch two (P = 0.009).  All four 
treatment groups, CON, CALFVAC, COWVAC and BOTH, had significantly different titers (P 
< 0.001) from each other during the feedlot phase with the CALFVAC calves having the highest 
average titer followed by BOTH calves (Figure 5.1).  Due to the nature of the study design, when 
a longitudinal data analysis of SRPAb was performed accounting for the repeated samplings of 
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the same animal over time, a significant three-way interaction between time, cow treatment and 
calf treatment was identified (P = 0.008; Figure 5.1).   
Upon feedlot entry there was an overall fecal E. coli O157:H7 prevalence of 34% among 
calves.  The fecal E. coli O157 prevalence at entry was CON (25%), CALFVAC (19%), 
COWVAC (32%) and BOTH (15%) which were not significantly different from one another (P 
> 0.05; Figure 2).  E. coli O157 fecal prevalence based on just the calf vaccination treatment was 
vaccinate (17%) and placebo (31%).  At slaughter, overall fecal E. coli O157 prevalence 
decreased slightly to 27%.  Fecal E. coli O157 prevalence at slaughter was CON (22%), 
CALFVAC (32%), COWVAC (15%) and BOTH (39%) which were not significantly different 
from one another (P > 0.05; Figure 5.2).  E. coli O157 fecal prevalence based on just the calf 
vaccination treatment was vaccinate (36%) and placebo (17%).  There was an unequal 
distribution of shedding prevalence between pens.  Three of the eight pens had fecal E. coli O157 
prevalence greater than 45%, two vaccinate pens and 1 placebo pen.  One pen had a prevalence 
of 13% while the remaining four had a prevalence of 4% or less.  Seventeen percent (11/65) of 
the calves shedding E. coli O157 at slaughter were also shedding at feedlot entry.  Nearly all 
(10/11) of these calves were from one of the three very high prevalence pens (Figure 5.3).  Fecal 
shedding of E. coli O157 on arrival to the feedlot was not correlated to fecal shedding at 
slaughter (Spearman‟s Rho = -0.02; P = 0.91).  There were no significant effects of cow or calf 
E. coli O157:H7 SRP vaccination treatment on feedlot health or performance of calves (P > 0.05; 
Table 5.1).  There were also no vaccination effects on the prevalence of lung lesions or liver 
abscess (P > 0.05; Table 5.1), nor the number of morbidities, re-treatments or mortalities (P > 
0.05; Table 5.1). 
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Discussion 
Nearly all of the previously reported studies for pre-harvest E. coli O157 control have 
been performed on cattle in the feedlot (reviewed in Lejune & Wetzel 2007; Sargeant et al. 2007; 
Loneragan & Brashears 2005).  This is the first trial to study the effects of vaccination of the 
dam in order to prevent colonization of the calf pre-harvest, through passive transfer, using the 
SRP vaccine technology.  Our laboratory had previously reported the successful passive transfer 
of E. coli O157:H7 SRP specific antibodies using a subsample of calves from the current study 
(Wileman et al. 2010).  Protection of neonates from disease through manipulation of colostral 
components via vaccination of the dam pre-partum is a long studied method for pathogenic viral 
and bacterial diseases (Acres et al. 1979; Fulton et al. 2004; vanDrunen et al. 2008).  However, 
protection of calves against a relatively non-pathogenic commensal organism through passive 
immunization is much less studied.  A small study done in Japan also showed successful passive 
transfer of E. coli O157 antibodies to calves but did not follow the calves to report whether this 
was protective (Widiashi et al. 2004).  Interestingly, a study in Argentina examining the ability 
of bovine colostrum-derived antibody at inhibiting hemolytic activity of attaching and effacing 
E. coli found that colostral lactoferrin was also very important in inhibition of hemolytic activity 
(Vilte et al. 2008).  Lactoferrin is an iron-binding glycoprotein in colostrum and milk that has 
inflammatory, antimicrobial and immunomodulatory functions (Brock 2002).  Thus lactoferrin 
and the SRP based technology are combating the E. coli organism by using its need for iron 
against itself (Neilands 1995).  It would be assumed that the combination approach of antibodies 
against the iron acquisition proteins and lactoferrin sequestering free-iron stores that colonization 
of E. coli O157 early in the life of cattle would be additively inhibited.  However throughout the 
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feedlot phase of the current study, fecal E. coli O157 prevalence remained at elevated levels 
through harvest. 
There was a significant increase in the prevalence of E. coli O157 from the time of 
weaning (0.6% prevalence) until the time of harvest (27% prevalence).  What caused the increase 
is not known but it does mirror other reports where prevalence of E. coli O157 was low (0-1.9%) 
in calves while on pasture (Gannon et al. 2002; Riley et al. 2003; Sargeant et al. 2000).  In a 
similar longitudinal trial Gannon et al. (2002) demonstrated the apparently cyclic nature of E. 
coli shedding as between 1-7 weeks of age fecal prevalence was 25%, then after turning out to 
pasture the prevalence went to 0% only to return 6-14% by two weeks post-weaning.  The 
current study found a similarly increasing prevalence with the branding time (already on grass) 
prevalence of 0%, weaning prevalence of 0.6%, feedlot entry prevalence of 34% and a harvest 
prevalence of 27%.  Unlike the Gannon study, the current study did not sample calves prior to 7 
weeks of age but did follow the calves through until harvest.  The prevalence estimates reported 
for the feedlot and harvest phases of this study are within many of the previously reported ranges 
of feedlot prevalence (Renter & Sargeant 2002; Lejune et al. 2004; Elder et al. 2000; Smith et al. 
2001; Chapman et al. 1997).  
The pen-level fecal E. coli O157 prevalence at feedlot arrival was not correlated with 
fecal prevalence at harvest.  Figure 3 illustrates the range of fecal prevalence observed in this 
trial with 3 pens (1 placebo & 2 vaccinate) with a very high prevalence compared to the other 
pens.  The interesting finding was that 10 of the 11 calves that were shedding E. coli O157 at 
entry to the feedyard and at harvest were from these three pens.  It is possible that these 11 calves 
are super-shedders and are largely responsible for the increased prevalence in these pens, but 
unfortunately quantitative culture was not performed on fecal samples in this trial to validate 
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this.  This could explain the large increases in shedding in these three pens from entry to harvest 
as well as finding these animals shedding E. coli O157 on two occasions 168 days apart.  
Previous studies have found that the amount of fecal shedding and the duration of fecal shedding 
of E. coli O157 are increased in super-shedders and is likely a significant contributor to between 
animal transmission (Naylor et al. 2003; Omisakin et al. 2003; Matthews et al. 2006).  Therefore 
the possibility of too large of, and persistent of a challenge in these pens may have resulted in the 
lack of difference between placebo and vaccinate groups.  However, Fox et al. (2009) showed 
that the SRP vaccine given three times was effective in stopping super-shedders.  The three doses 
administered in that trial were all given during the feedyard phase.  The results from this trial 
combined with those of Fox et al. would suggest that vaccination should occur during the 
feedyard phase of production. 
In this trial the E. coli O157:H7 specific antibody titers peaked shortly after feedlot 
arrival and were lower at the time of harvest (Figure 5.1).  Although beyond the scope of this 
study, it is possible that the serum titer levels dropped below the level of protection that would 
have resulted in a statistically significant difference in fecal shedding between vaccinates and 
placebos.  The previously reported studies (Thomson et al. 2009; Fox et al. 2009) using the same 
vaccine all had the final booster-vaccination administered to yearling cattle within 60 days of 
harvest and all vaccinations administered within 100 days of harvest.  In the current trial the first 
vaccination was given at approximately 75 days of age with the second vaccination occurring at 
187 days of age and the final vaccination at 217 days of age.  This protocol results in 112 days 
between the first vaccination and the second and 168 days from final vaccination until harvest.  
This approach was selected to reflect industry applicable handling time points for administration 
of the SRP vaccine due to its three dose label.  The ability to spread the three doses over normal 
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handling time points would be much more preferred than adding an additional handling time 
during the feedlot phase of the production cycle when performance of the cattle is critical.  When 
the previously reported studies results and intervals from final vaccination to harvest are 
compared to the current study‟s results and interval from final vaccination to harvest, it indicates 
that the timing of the final vaccination relative to the point of harvest could be very important.   
The enrichment step in the fecal culture protocol was changed for only the harvest time 
point samples to a six hour enrichment rather than a 24 hour enrichment.  This decision was 
made to aid the laboratory personnel in identification of suspect colonies based on a personal 
conversation with researchers at the U.S. Meat Animal Research Center (MARC) about a 
previous study performed there (Barkocy-Gallagher et al. 2002).  The study reported 
significantly improved sensitivity using the method developed at the MARC due to less 
enrichment time for competing commensal organisms resulting in less commensal growth on 
selective media and greater recovery rates of injured cells.  The extent to which this affected the 
results of this trial is unknown as samples were not split and tested in parallel with the two 
incubation times.  In theory the sensitivity should be increased equally across treatment groups 
resulting in an equal net difference between them. However Barkocy-Gallagher et al. did not 
discuss whether this affected the lower detectable limit of the procedure.  If this did occur than 
the samples that would have been undetectable with the previous procedure would now become 
detectable with the current procedure changing a negative sample into a positive sample.  The 
SRP vaccine has been shown to decrease the amount of E. coli O157 shed in the feces of cattle 
(Thomson et al. 2009), thus it is plausible that this decrease could have resulted in a greater 
number of negative samples, under the longer enrichment procedure in the feedlot entry samples 
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and a greater number of positive samples, under the shorter enrichment procedure in the harvest 
samples.  Whether this is true and to what extent is unknown. 
There were no adverse performance or health effects identified in this study due to E. coli 
O157:H7 SRP vaccination.  There was no difference between SRP vaccinated cattle and placebo 
with regards to fecal E. coli O157 prevalence upon entry to the feedyard and at harvest using a 
modified three dose regimen.  However, SRP vaccination did result in a significant increase in 
serum antibody titers compared to placebo.  Further study into the different industry applicable 
handling time points where the vaccine is likely to be administered is warranted as it appears that 
timing of vaccination near slaughter may be important.  SRP vaccination is an effective strategy 
for the reduction of fecal shedding of E. coli O157:H7 in feedlot cattle.  The timing of when this 
vaccination is applied appears to be a major determinant of its efficacy at reduction in fecal E. 
coli O157:H7 at the time of harvest.  E. coli O157:H7 SRP vaccine technology is only one part 
of a comprehensive food safety program that when implemented appropriately will help maintain 
beef as a safe and nutritious food source. 
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Table 5.1:  Summary of feedlot performance and carcass effects by calf vaccination treatment. 
Vaccinate or placebo indicates the calf vaccine treatment only, no cow vaccine 
treatments were found to be significant (P > 0.10). Standard error of the mean (SEM). 
Parameter Vaccinate Placebo SEM P-value 
Wean weight (lbs) 488 487 15 0.96 
Feedlot entry weight (lbs) 528 527 15 0.99 
Final bodyweight (lbs) 1128 1134 10 0.67 
Feedlot ADG (lbs/d) 3.06 2.91 0.16 0.50 
Weaning thru slaughter ADG (lbs/d) 2.79 2.65 0.15 0.50 
HCW (lbs) 750 757 13 0.70 
Marbling 44.47 43.85 0.90 0.64 
Back fat (inches) 0.44 0.42 0.025 0.70 
REA (inches) 12.67 12.74 0.12 0.70 
KPH (%) 2.96 3.15 0.26 0.61 
YG 2.97 2.99 0.13 0.93 
DMI (lbs/day) 22.48 22.59 0.03 0.06 
F:G 6.35 6.51 0.14 0.44 
Liver Abscess (Risk) 0.28 0.26 -- 0.87 
Lung Lesion (Risk) 0.37 0.42 -- 0.65 
First Pull (Risk) 0.12 0.09 -- 0.51 
Re-treatment (Risk) 0.01 0.01 -- 0.98 
Mortality (Risk) 0.03 0.01 -- 0.42 
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Figure 5.1: Differences in serum anti-E. coli O157:H7 SRP antibody by cow treatment 
and calf treatment at each sampling time point.  The study design and the corresponding 
immunological response of the calves resulted in a three-way interaction between cow 
treatment*calf treatment*time (P = 0.008). 
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Figure 5.2: Fecal E. coli O157:H7 prevalence by treatment group at feedlot entry and at 
slaughter.  There were no differences between treatment groups (P > 0.05). 
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Figure 5.3: Fecal E. coli O157:H7 prevalence in feedlot pens by calf treatment at feedlot 
entry and at slaughter.   
 
